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ABSTRACT 
Metabolic syndrome (MetS) affects approximately 25% of the adult population of the 
world and represents a public health concern with high socioeconomic impact worldwide. Latin 
American populations exhibit a high prevalence of MetS, similar or even higher than developed 
countries. This complex and progressive disorder can develop over many years as a cluster of 
conditions characterized by a constellation of metabolic abnormalities. Specific guidelines have 
not yet been established for the treatment of MetS per se. The increased prevalence of MetS has 
been associated with a greater risk of developing type 2 diabetes mellitus (T2DM) and 
cardiovascular disease (CVD). In fact, new anti-diabetic drugs that do not display undesirable 
side effects, such as hepatotoxicity, edema and weight gain, are in great demand. For these 
reasons, the overall goal of this study was centered on four molecular targets: peroxisome 
proliferator-activated receptors (PPARs), liver X receptors (LXRs), nuclear factor-κB (NF-κB), 
and inducible nitric oxide synthase (iNOS) which are key regulators of various processes leading 
to metabolic disorder and inflammation. As a part of inflammatory pathway, activation of NF-κB 
leads to insulin resistance and by blocking this pathway, insulin resistance and the resultant 
T2DM can be prevented. In contrast, activators of PPAR and PPAR are effective in lowering 
blood lipids and sugar and have been considered useful in the treatment of obesity and diabetes. 
Like the PPARs, LXR suppresses production of inflammatory mediators in a manner reciprocal 
to its regulation of lipid metabolism. In order to explore natural products working through these 
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specific pathways this dissertation was focused on Panamanian flora as a primary source. A total 
of 75 plant species belonging to 71 genera and 41 families were screened for their effects on the 
selected targets trough cellular assays. Due to a lack of literature available on the biological 
activity towards MetS and lack of the phytochemical characterization, two plants (Talisia 
nervosa and Odontadenia puncticulosa) were selected for bioassay-guided fractionation through 
PPARα and PPARγ activation assay. The current study relied on Panamanian flora as a source of 
new therapeutic agents directed toward the mitigation of metabolic abnormalities.   
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CHAPTER 1                                                                                      
INTRODUCTION 
1.1 Metabolic Syndrome 
1.1.1 Definition 
Metabolic syndrome (MetS) is a complex, progressive disorder that can develop over 
many years as a cluster of conditions characterized by a constellation of metabolic abnormalities, 
which include abdominal obesity, hyperglycemia, insulin resistance, atherogenic dyslipidemia 
(high triglycerides and low high-density lipoprotein (HDL)-cholesterol) and hypertension (Paul 
L. Huang, 2009; Zimmet, et al., 2005). These components are shown in Figure 1.1. 
Historically, Kylin (Kylin, 1923) was the first to describe this complex metabolic 
disorder as the clustering of hyperglycemia, hypertension and gout. Subsequently, in 1947 Vague 
(Vague, 1947)  indicated that upper body adiposity was the obesity phenotype marker most 
commonly associated with type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) 
(Eckel, et al., 2005).  This metabolic disorder was previously called “syndrome X” by Reaven 
and “insulin-resistance syndrome” among other names (R. A. DeFronzo and Ferrannini, 1991; 
Reaven, 1988). In order to develop an internationally recognized definition for MetS, several 
criteria have been widely revised and proposed by a number of specialist groups and 
organizations, such as the World Health Organization (WHO), the European Group for the study 
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of Insulin Resistance (EGIR), the International Diabetes Federation (IDF), the National 
Cholesterol Education Program Adult Treatment Panel III (NCEP:ATPIII), the American Heart 
Association/National Heart, Lung, and Blood Institute (AHA/NHLBI), and the American 
Association of Clinical Endocrinology (AACE) (Alberti, et al., 2006; Kassi, et al., 2011; Ritchie 
and Connell, 2007). Table 1.1 summarizes the most commonly accepted definitions.  
          
 Figure 1.1 Components of MetS. The figure was reproduced with appropriate permission from the 
Company of Biologists publishing group (Huang, 2009). 
 3 
 
Table 1.1 A comparison of some of the most widely used definitions for MetS. Adopted and modified 
from Huang, 2009. 
WHO (1998) EGIR (1999) IDF (2005) NCEP ATP III (2005 revision)
Absolutely required  Insulin resistance
* 
(IGT, IFG,T2D 
or other evidence of IR) 
Hyperinsulinemia
‡
 (plasma
insulin >75
th
 percentile)
Central obesity (waist
circumference
§
): ≥94 cm (M),
≥80 cm (F)
None
Criteria Insulin resistance or diabetes,
plus two of the five criteria below
Hyperinsulinemia, plus two of the 
four criteria below
Obesity, plus two of the five 
criteria below
Any three of the five criteria below
Obesity Waist/hip ratio: >0.90 (M),
>0.85 (F); or BMI >30 kg/m
2
Waist circumference: ≥94 cm (M),  
≥80cm (F)
Central obesity already
required
Waist circumference: >40 inches 
(M), >35 inches (F)
Hyperglycemia Insulin resistance already
required
Insulin resistance already
required
Fasting glucose  ≥100 mg/dl Fasting glucose ≥100 mg/dl or Rx
Dyslipidemia TG ≥150 mg/dl or HDL-C:
<35 mg/dl (M), <39 mg/dl (F)
TG ≥177 mg/dl or HDL-C <39 
mg/dl
TG ≥150 mg/dl or Rx TG ≥150 mg/dl or Rx
Dyslipidemia (second,
separate criteria)
HDL-C: <40 mg/dl (M),
<50 mg/dl (F); or Rx
HDL-C: <40 mg/dl (M),
<50 mg/dl (F); or Rx
Hypertension ≥140/90 mmHg ≥140/90 mmHg  or Rx >130 mmHg systolic or >85 
mmHg
>130 mmHg systolic or >85 mmHg 
diastolic or Rx
Other criteria Microalbuminuria
†
*
IGT, impaired glucose tolerance; IFG, impaired fasting glucose; T2D, type 2 diabetes; IR, insulin resistance; other evidence includes euglycemic clamp studies.
†
Urinary albumin excretion of ≥20 μg/min or albumin-to-creatinine ratio of ≥30 mg/g.
‡
Reliable only in patients without T2D.
§
Criteria for central obesity (waist circumference) are specific for each population; values given are for European men and women.
BMI: body mass index; F: female; M: male; HDL-C: high-density lipoprotein cholesterol; TG: triglycerides; Rx: pharmacologic treatment.  
1.1.2 Prevalence  
This devastating disease represents a public health concern because the prevalence of 
MetS is steadily increasing worldwide, as a consequence of the global epidemic of obesity. The 
IDF estimated that nearly one-fourth of the world’s adult population has MetS.  
The prevalence of MetS has been consistently influenced by the definition applied as well 
as the ethnicity, age, gender and race of the population under study.  According to National 
Health and Examination Survey (NHANES) 2003-2012, the overall prevalence in the United 
States was 33% in adults, using the NCEP:ATPIII criteria. Estimates were higher in women 
(35.6%) compared to men (30.3%). When stratified by race/ethnicity, the highest prevalence of 
MetS was seen in Hispanics (35%), followed by non-Hispanic whites (33%) and blacks (33%). 
MetS becomes more prevalent with each decade of life where the prevalence increased with age 
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from 18.3% to 46.7% among those aged 20-39 years and ≥60 years, respectively. More than 50% 
of women and Hispanics had MetS among the group aged 60 years or older (Aguilar, et al., 
2015). A summary of the results is shown in Figure 1.2. 
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Figure 1.2 Age-Specific Prevalence of MetS by Sex and Race/Ethnicity, 2003-2012. Adopted and 
modified from Aguilar, et al., 2015. 
 
In addition, the Latin American populations exhibit a high prevalence of MetS, similar or 
even higher than developed countries. It is attributed to changes in their lifestyle, migration from 
rural to urban areas and a higher susceptibility to accumulate abdominal fat and develop more 
insulin resistance compared to other ethnically different populations (Cuevas, et al., 2011; 
Marquez-Sandoval, et al., 2011). 
1.1.3 Morbidity and Mortality 
Epidemiological studies have shown that MetS is associated with a greater risk of 
developing T2DM, CVD and stroke (Grundy, et al., 2004; Malik, et al., 2004). As a result, the 
risk of CVD has been related to the atherogenic dyslipidemia which comprises a triad of high 
blood triglyceride concentrations, increased low-density lipoprotein (LDL), and decreased HDL 
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(Giugliano, et al., 2006), whereas the risk of developing T2DM significantly increases with the 
presence of insulin resistance (Hanson, et al., 2002). In addition, several studies have shown the 
link between the increased risk of CVD and T2DM with abdominal obesity (Zhu, et al., 2002).  
MetS and its cluster of metabolic abnormalities have been associated with mortality. As 
an example, this metabolic disorder was connected with a twofold increase in cardiovascular 
outcomes and a 1.5-fold increase in all-causes of death (Mottillo, et al., 2010). Furthermore, 
numerous studies have also examined the correlation between the presence of MetS and the risk 
of T2DM. According to these evidences, the existence of this metabolic disorder increases the 
risk and the prognosis of new-cases of T2DM (Sattar, et al., 2008). In fact, individuals with MetS 
have five times higher risk of developing T2DM compared with those without the syndrome 
(Ford, et al., 2008). 
1.1.4 Pathogenesis  
The pathogenesis of MetS is complex and many key aspects remain unclear. 
Nevertheless, two potential causative factors: abdominal obesity and insulin resistance appear to 
be the core of the etiology that explains the clustering of metabolic disturbances. Other risk 
factors have also been implicated in the progression of MetS, such as aging, genetic profile, 
physical inactivity, hormonal deregulation, and proinflammatory state (Grundy, et al., 2004). 
1.1.4.1 Obesity 
The WHO estimated that globally the prevalence of obesity has more than doubled 
between 1980 and 2014 (WHO). This worldwide epidemic has been the most significant driving 
force involved in the high prevalence of MetS. 
Obesity can be related with higher CVD risk as well as promoters of hypertension, 
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hyperglycemia, insulin resistance, high serum triglycerides and low HDL-cholesterol (Alberti, et 
al., 2006). In particular, several studies have shown that accumulation of body fat in the 
abdomen, measured by waist circumference, is a predictive feature of these conditions due to the 
variety of bioactive substances released by the excess of adipose tissue (Carr, et al., 2004).  
1.1.4.2 Insulin Resistance 
Insulin resistance has shown evidence for its central role in the development of MetS and 
has been linked to obesity (Nesto, 2003). This metabolic abnormality has a marked connection 
with proinflammatory state and atherogenic dyslipidemia. However, it is less correlated with 
prothrombotic state and hypertension. In fact, atherogenic dyslipidemia and fatty liver are 
induced when some excess, nonesterified fatty acids are mobilized to the liver because the 
insulin resistant muscle is overloaded with lipid (Grundy, et al., 2004). 
1.1.4.3 Other Factors 
In addition to obesity and insulin resistance there are other important factors that also 
influence the clinical expression of MetS. To illustrate, genetic tendencies have been reported 
toward visceral fat accumulation, insulin resistance and hypertension (Moller and Kaufman, 
2005). Physical inactivity has a significant effect on muscle insulin sensitivity and causes 
obesity. The aging process is characterized by an accumulation of body fat, mainly in the 
abdominal area, and by a decrease of muscle mass; which are the major contributors of insulin 
resistance. Moreover, a proinflammatory state has been implicated directly in causation of 
atherogenesis as well as insulin resistance. Lastly, several endocrine factors have been involved 
with the pathological changes in body-fat distribution (Grundy, et al., 2004). A summary of risk 
factors is shown in Figure 1.3. 
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Figure 1.3 The relationship between the risk factors involved in the pathogenesis of MetS. 
 
1.1.5 Therapeutic Approaches  
Specific guidelines have not yet been established for the treatment of MetS per se due to 
three main reasons:  
 The pathogenesis of this disorder is unclear. 
 The criteria for the diagnosis vary. 
 There is uncertainty of the specific constellation of metabolic abnormalities that 
should be treated. 
Therefore, current treatments are directed toward correction of individual risk factors. 
Life style modification and pharmacotherapy are some of the diverse approaches for the 
treatment of MetS (Grundy, et al., 2004).  
Agonists of peroxisome proliferator-activated receptors (PPARα, PPARγ, PPARδ), 
represent a recognized line of therapy for the treatment of the abnormalities associated with 
MetS. This is attributed to their ability to regulate many aspects related to lipid metabolism and 
glucose homeostasis (Akiyama, et al., 2005). For example, the fibrates family (fenofibrate, 
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bezafibrate, gemfibrozil) used for atherogenic dyslipidemia can activate PPARα and 
thiazolidinedione (pioglitazone, rosiglitazone), an insulin-sensitizer agent is a PPARγ activator 
(Mansour, 2014). Novel PPARs drugs with broad safety margins and therapeutic potentials for 
MetS are required. 
Medicinal plants represent an excellent source of biologically active compounds for the 
treatment of MetS because of the presence of a wide range of phytochemicals with diverse 
metabolic effects. For instance, cinnamon (Cinnamomum aromaticum) has been used historically 
for the treatment of diabetes and studies have shown lipid-lowering, anti-diabetic and anti-
hypertensive effects. In addition, the alkaloid berberine, which is present in the root and bark of 
several plants, has been reported as insulin-sensitizer, lipid-lowering and anti-hypertensive agent. 
Similarly, bitter gourd (Momordica charantia) has been used in traditional medicine to treat 
diabetes-related conditions and has been associated with the regulation of glucose and lipid 
metabolism (Cicero and Colletti, 2015; Yin, et al., 2008). 
 In summary, MetS is a medical priority worldwide, as it comprises a cluster of risk 
factors, which requires the development of better approaches for the prevention and management 
of the syndrome. Due to the inter-connection between the multiple defects associated with MetS, 
it is urgent to develop unique potential strategies that address multiple risk factors related to this 
disease. 
Therefore, this dissertation was focused on four molecular targets (PPARs, NF-κB, 
iNOS, and LXRs) as a result of their close association with metabolic disorders such as T2DM, 
hypercholesterolemia, inflammation, and obesity. 
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1.2 Molecular Targets 
1.2.1 Peroxisome Proliferator-Activated Receptors (PPARs) 
1.2.1.1 Isoforms 
PPARs were discovered in 1990 as key players in the response to peroxisome 
proliferators and the genetic sensor for fat metabolism (Issemann and Green, 1990). The three 
PPAR isoforms: PPAR, PPARβ/, and PPAR (Dreyer, et al., 1992; Kliewer, et al., 1994) are 
ligand-activated transcription factors that belong to the nuclear hormone receptor (NHR) 
superfamily (Schoonjans, et al., 1997). These isoforms possess four functional domains. A 
ligand-independent activation function (AF-1) found in close proximity to the N terminus of the 
receptor. The DNA binding domain (DBD) which consists of two zinc fingers that specifically 
bind peroxisome proliferator response elements (PPREs) in the promoter region of PPAR-
responsive genes.  The ligand binding domain (LBD) appears to be quite large in comparison 
with other nuclear receptors which allow the PPARs to interact with a broad range of structurally 
diverse ligands. A ligand-dependent activation domain (AF-2) is located in the C terminus of the 
LBD. The DBD and the LBD are the most highly conserved regions across the receptor isoforms 
with 60% to 80% homology (Joel Berger and Moller, 2002). In the presence of a ligand, PPARs 
form obligate heterodimers with another nuclear receptor, the retinoid X receptor (RXR), which 
bind to PPREs, present in the regulatory domains of target genes. Upon binding, the 
conformation of the receptor is altered, facilitating the formation of high-affinity interactions 
with coactivators that remodel the chromatin and activate the cellular transcription machinery 
(Desvergne and Wahli, 1999). 
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1.2.1.2 Distribution and Physiological Functions 
PPAR was the first to be identified as PPAR receptor. It is mostly present in tissues 
characterized by high rates of fatty acid catabolism and is highly expressed in brown adipose 
tissue, followed by liver, kidney, heart, and skeletal muscle (Auboeuf, et al., 1997). This receptor 
regulates genes involved in several aspects of lipoprotein metabolism and fatty acid oxidation. 
The activation of PPAR upregulates the expression of several catabolic enzymes that are 
involved in mitochondrial and peroxisomal β-oxidation, and also genes that are required for the 
maintenance of the redox balance during the oxidative catabolism of fatty acids (Willson, et al., 
2000). The transcriptional activity of PPAR is stimulated by a range of endogenous saturated 
and unsaturated fatty acid, such as palmitic acid, oleic acid, linoleic acid, and arachidonic acid 
(Goettlicher, et al., 1992). In the same way, PPAR serves as the receptor for a structurally 
diverse class of compounds, including hypolipidemic drugs such as fibrates (clofibrate, 
fenofibrate, bezafibrate, gemfibrozil) and statins (simvastatin, atorvastatin) (Staels, et al., 2008).  
PPARβ/ shows a widespread tissue distribution, mainly in brain, macrophages, liver, 
lung, adipose tissue, and skeletal muscle (Willson, et al., 2000). It remains the least understood 
PPAR isoform due in part to its ubiquitous expression and the paucity of potent and selective 
ligands (Bishop-Bailey, 2000). Nevertheless, a growing body of evidence has implicated 
PPARβ/ as an important regulator of fatty acid catabolism, energy expenditure, reverse 
cholesterol transport, lipid homeostasis, and glucose metabolism (Akiyama, et al., 2004; 
Leibowitz, et al., 2000; Luquet, et al., 2005). Thus far reported candidates for endogenous 
activators of PPARβ/ are eicosanoids (prostaglandin A1, prostaglandin D2), fatty acids, 
triglycerides and prostacyclin (H. Eric Xu, et al., 1999). Moreover, a number of synthetic 
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compounds including L-165041, GW501516, GW0742, and GW610742 have been designed as 
selective ligands for this receptor (Brunmair, et al., 2006; Oliver, et al., 2001). 
PPAR is the best characterized receptor and the most extensively investigated of the 
three PPAR isoforms. Expression of PPAR is highest in adipose tissue with lower levels 
expressed in heart, kidney, liver, colon, spleen, intestine, macrophages, and skeletal muscle 
(Fajas, et al., 1997). This PPAR isoform is widely recognized as a pivotal transcription factor in 
the regulation of adipocyte gene expression and differentiation (Debril, et al., 2001). Its 
participation in adipocyte differentiation involves a complex coordinated signaling cascade with 
other families of transcription factors (Bruce M. Spiegelman and Flier, 1996). In addition, 
PPAR modulates metabolism and inflammation, as well as controls cell proliferation and plays 
a significant role in the regulation of target genes involved in lipid metabolism and glucose 
homeostasis (Heikkinen, et al., 2007; Tontonoz and Spiegelman, 2008). Several endogenous 
ligands for PPAR have been identified, including fatty acids (linoleic acid, linolenic acid, 
arachidonic acid) and eicosanoids (eicosapentaenoic acid, 15-deoxi Δ12,14-prostaglandin J2) 
(Forman, et al., 1995; H. Eric Xu, et al., 1999). Furthermore, synthetic agonists have been 
developed, such as thiazolidinedione class of antidiabetic agents (pioglitazone, rosiglitazone, 
troglitazone) which represents the best studied class of PPAR agonists (Lehmann, et al., 1995; 
B. M. Spiegelman, 1998; Yki-Jaervinen, 2004). 
In summary, isoforms of the PPAR family of nuclear receptors modulate the expression 
of a vast array of target genes that play a central role in regulating glucose metabolism, 
inflammation, cell differentiation, lipid, and cholesterol metabolism (Tom Hsun-Wei Huang, et 
al., 2009) as shown in Figure 1.4.  
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PPARs have emerged as therapeutic targets with widespread impact in the treatment of 
MetS, T2DM, obesity and CVD (Balint and Nagy, 2006; Joel P. Berger, et al., 2005). As a 
consequence, the pharmaceutical industry has invested enormous amount of its drug discovery 
efforts into developing PPAR modulators with increased therapeutic impact and without harmful 
side effects.   
1.2.1.3 PPAR Agonists in the Treatment of Dyslipidemia 
An elevation in circulating levels of triglycerides and LDL cholesterol, along with 
decreased levels of HDL cholesterol, comprise a dyslipidemic profile common to many patients 
with MetS (Akiyama, et al., 2005). The fibrate class of PPARα agonists is effective in lowering 
serum triglycerides (30% to 50%) and free fatty acids, as well as improving cholesterol profiles 
(increasing HDL cholesterol by 10% to 22% and decreasing LDL cholesterol by 10% to 25%) 
(Verges, 2004) primarily through increased clearance and decreased synthesis of triglyceride rich 
very-low-density lipoprotein (VLDL) (Staels, et al., 1998).  
Fibrates such as bezafibrate, gemfibrozil, clofibrate, fenofibrate and ciprofibrate have 
been used in clinical practice as hypolipidemic agents for decades (Tenenbaum and Fisman, 
2012). 
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Figure 1.4 PPAR isoforms signaling pathways and their ligands (natural and synthetic). The figure was 
reproduced with appropriate permission from the Elsevier publishing group (Huang, et al., 2009). 
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1.2.1.4 PPAR Agonists in the Management of Insulin Resistance and T2DM 
The decreased ability of insulin to regulate glucose metabolism is known as insulin 
resistance. This chronic disorder strongly predisposes and increases the risk of life threatening 
clinical conditions such as MetS, T2DM and coronary artery disease (Evans, et al., 2005).  
Taking a global perspective, T2DM is the predominant clinical condition of diabetes 
which accounts for 90-95% of all cases worldwide (Qiong Liu, et al., 2010). This disease is 
characterized by impaired insulin secretion resulting from inadequate pancreatic β-cells function 
and insulin resistance in liver, adipose tissue and skeletal muscle (Ralph A. DeFronzo, 2004). 
Moreover, many patients with T2DM will develop long-term complications like blindness, 
nephropathy, neuropathy, ketoacidosis, heart disease, and stroke (Nathan, 1993). As a 
consequence, T2DM represents a major and growing public health problem with great economic 
impact reflected in health care and loss of productivity. Currently, there is estimated 415 million 
people worldwide suffering from diabetes where the United States and the Latin American 
region represent 29.3 and 41.1 million people, respectively. In fact, around 642 million people 
will be affected with the disease by the year 2040 and every six seconds a person dies from 
diabetes (IDF 2015). Therefore, developing novel anti-diabetic drugs has become an urgent need.     
Thiazolidinediones, agonists of PPARγ, comprise a class of insulin-sensitizing agents that 
are of particular interest for treating patients with T2DM because they reduce insulin resistance 
and improve insulin sensitivity, resulting in a reduction of fasting plasma glucose, insulin and 
free fatty acids (Goldstein, 1999; Mudaliar and Henry, 2001). In fact, this class of insulin-
sensitizing agents shows direct effects on lipid metabolism in adipose tissue and secondary 
effects on lipid and glucose metabolism in liver and skeletal muscle (Jiang, et al., 2002; Way, et 
al., 2001). Troglitazone was the first drug in this class approved in 1997 but was later withdrawn 
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from the market due to rare but serious cases of hepatotoxicity (Kumar, et al., 1996; Watkins and 
Whitcomb, 1998). Pioglitazone and rosiglitazone are currently available in the market as oral 
hypoglycemic drugs and have not been linked with the hepatic adverse events, suggesting that 
hepatotoxicity may not be a class effect of PPARγ agonists (Kawamori, et al., 1998; Y. 
Miyazaki, et al., 2001; Yoshinori Miyazaki, et al., 2002). These drugs represent an important 
advance in the treatment of T2DM when used as monotherapy or in combination with other 
therapies.  
1.2.1.5 Potential Therapeutic Roles of PPAR Agonists in Vascular and Metabolic Disorders 
Although dyslipidemia is a central causative factor of coronary heart disease, factors such 
as vascular dysfunction, vascular remodeling, and inflammation are also involved. Evidence 
indicates that PPARα agonists might also have direct effect in the arterial wall, which could 
contribute to the beneficial effect of these ligands in atherosclerosis (Ericsson, et al., 1997; 
Rubins, et al., 1999; Ruotolo, et al., 1998). This proposition is feasible because vascular cells 
express significant amounts of PPARα and have numerous crucial roles in the atherogenic 
process (Marx, et al., 2004). Furthermore, endothelial dysfunction is associated with the 
development of atherosclerosis and PPARα agonists have shown to block cytokine-mediated 
induction of vascular cell adhesion molecule 1 by inhibiting the NF-κB signaling pathway in 
endothelial cells (Marx, et al., 1999). On the other hand, PPARα and PPARγ agonists have 
shown to increase nitric oxide expression and release, respectively, from endothelial cells which 
are fundamental to maintain their normal function (Calnek, et al., 2003; Goya, et al., 2004). 
Highly potent compounds that are dual PPARα/PPARγ agonists are ideal agents for 
managing MetS. For instance, fibrates improve a range of atherogenic dyslipidemias (Guerre-
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Millo, et al., 2000) whereas thiazolidinediones improve glycemic control (Moller, 2001) and 
these agents also influence many other components of the MetS such as hypertension, vascular 
dysfunction and inflammation. As a result, prospects for the management of patients with MetS 
will have a better future if single compounds can bring together the antilipidemic effects of 
PPARα with the anti-diabetic effects of PPARγ (Balakumar, et al., 2007; Fievet, et al., 2006). 
There are dual PPARα/PPARγ agonists, collectively known as glitazars, in pre-clinical 
and clinical development. Saroglitazar was the first glitazar to be approved for clinical use in 
2013 by the Indian regulatory authority Drug Controller General of India (Sharma, et al., 2015). 
Nevertheless, safety issues can result from synergic toxic effects from simultaneous activation of 
PPARα and PPARγ and they will require to be addressed.  
1.2.1.6 Safety Issues 
PPAR activating drugs have been used successfully to treat various components of MetS. 
However, significant dose limiting has been required to reduce the incidence of side effects 
(Scheen, 2004). The currently marketed thiazolidinediones agonists of PPARγ have been 
associated with undesirable side effects such as weight gain, fluid accumulation, and pulmonary 
and macular edemas leading to increased frequency of congestive heart failure (Guan, et al., 
2005; Nesto, et al., 2003). 
 In addition, troglitazone was withdrawn from the market after reports of severe 
idiosyncratic hepatotoxicity (Watkins and Whitcomb, 1998). Nevertheless, the mechanisms of 
hepatotoxicity have not been fully elucidated. Numerous mechanisms have been postulated; 
including inhibition of bile acid transport by troglitazone and its major metabolite, which may 
cause accumulation of toxic bile acid and subsequent liver injury (Chojkier, 2005). Besides, 
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chemically reactive metabolites of the drug may play a causative role (Kassahun, et al., 2001). 
On the other hand, carcinogenic potential has emerged as a major safety concern for 
PPAR agonist drugs. Data have shown that investigational PPAR agonists induce tumors at 
multiple sites in rodents and they occur in tissues with high PPAR receptor distribution, although 
the mechanisms of tumor induction are not known (Shearer and Billin, 2007). 
Therefore, the discovery of potential PPAR drugs that mitigate the harmful side effects of 
existing drugs has become an important approach in the pharmaceutical industry. Consequently, 
strategies to design and screen compounds for efficacy with improved therapeutic indexes are 
highly desirable.   
1.2.2 Nuclear Factor Kappa-B (NF-κB) 
1.2.2.1 Structure and Signaling Pathways 
NF-κB was first identified in 1986 as a transcription factor in B cells that binds to the 
enhancer element controlling immunoglobulin kappa light chain expression (Sen and Baltimore, 
1986). In mammalian cells there are five NF-κB family members that represent a group of 
structurally related and evolutionary conserved proteins which belong to the 
reticuloendotheliosis (Rel) family and are regulated via shuttling from the cytoplasm to the 
nucleus in response to cell stimulation (Birbach, et al., 2002). These proteins possess a 
structurally conserved 300 amino acid sequence called the REL region, which contains the 
dimerization, nuclear location, and DNA binding domains. In addition, they are expressed in the 
cytoplasm of nearly all cell types and their activity is controlled by a family of regulatory 
proteins, called inhibitors of NF-κB (IκB) (Hayden and Ghosh, 2004; Qiutang Li and Verma, 
2002). In fact, the activation of NF-κB by two major pathways, namely the canonical (classical) 
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and non-canonical (non-classic) NF-κB signaling pathway relies on the inducible 
phosphorylation of IκB inhibitory proteins by the IκB kinase complex (IKK) and subunits 
(Ghosh and Karin, 2002). 
1.2.2.2 Physiological Functions 
This inducible, ubiquitous transcriptional regulator acts as a central mediator of the 
human immune response and is involved in physiological and pathological processes such as 
tissue homeostasis and inflammation (Baldwin, 1996). At the molecular and cellular level NF-B 
regulates genes expression, cell apoptosis and proliferation (Lin, et al., 2010). In most cases NF-
B acts as a transcriptional activator by directly binding to the promoter to facilitate gene 
transcription. In quiescent cells, the active form of NF-B in cytosol remains bound to the 
inhibitory molecule, IBα. Upon stimulation by proinflammatory cytokines or oxidants, IBα is 
phosporylated by the upstream IKK, which leads to the polyubiquitination and degradation of 
IB by proteases, causing the release and translocation of NF-B complex into the nucleus. 
Activated NF-B subsequently binds to specific DNA sequences and regulated the expression of 
its target genes (Baker, et al., 2011; Fei Chen, et al., 1999) as shown in Figure 1.5. 
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Figure 1.5 NF-κB is constitutively bound to IkB molecules which confine its localization to the cytosol. 
IKK complex phosphorylation of serine residues on IkB promotes its polyubiquitination and degradation, 
thereby freeing NF-κB to enter the nucleus and activate transcription of target genes. The figure was 
reproduced with appropriate permission from the Elsevier publishing group (Baker, et al., 2011).  
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1.2.2.3 Inhibitors of NF-κB Activation  
Several non-steroidal anti-inflammatory drugs (NSAIDs) including sulindac, ibuprofen, 
aspirin, indomethacin, and COX-2 inhibitors have shown to suppress NF-κB activation by 
suppressing IKK activation and IκB degradation (Takada, et al., 2004). 
In addition, glucocorticoids up-regulate IκB gene expression, which then inactivates NF-
κB (Auphan, et al., 1995). 
Naturally occurring anti-inflammatory compounds such as epigallocatechin gallate 
(EGCG), eicosapentaenoic acid (EPA), curcumin, and luteolin are also able to block NF-κB 
activation at distinct steps of the pathway. For instance, apigenin and anacardic acid inhibit IKK, 
resveratrol inhibits p65 phosporylation, and epicatechin inhibits p65 translocation to the nucleus 
(Irfan Rahman, et al., 2006).         
In conclusion, inhibition of NF-κB activation by certain drugs has been found to be 
responsible for their ability to prevent oxidative stress and inflammation which could be 
beneficial in conditions of diabetes and MetS (Baldwin, 1996). 
1.2.3 Inducible Nitric Oxide Synthase (iNOS) 
1.2.3.1 Structure and Signaling Pathways 
Nitric oxide synthases (NOS) are enzymes that catalyze the conversion of L-arginine to 
nitric oxide (NO), a free radical molecule (Richard G. Knowles and Moncada, 1994). There are 
three NOS isoforms: endothelial NOS (eNOS) associated with the endothelium, neuronal NOS 
(nNOS) expressed in neurons and brain, and inducible NOS (iNOS), induced by cellular 
activation (R. G. Knowles, 1996). All three NOS enzymes are homodimers. They are 
catalytically active when dimerized and require two substrates, L-arginine, molecular oxygen, in 
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combination with several co-factors including nicotinamide-adenine-dinucleotide phosphate 
(NADPH), flavin adenine dinucleotide (FAD), flavin mononucleotide (FMN), and (6R)5,6,7,8- 
tetrahydro-L-biopterin (BH4) to generate NO (Foerstermann and Sessa, 2012).  
iNOS is expressed in macrophages, neutrophils, fibroblast, vascular smooth muscle, and 
endothelial cells (MacMicking, et al., 1997; Sethi and Dikshit, 2000). In addition, it produces NO 
in response to a vast array of stimuli, including endotoxin and endogenous pro-inflammatory 
mediators. The most prominent cytokines involved in iNOS activation are tumor necrosis factor-
α (TNFα), interleukin-1B (IL-1B), and interferon-γ (IFN- γ). Regulation of NO production via 
iNOS predominantly occurs during transcription and translation until substrate depletion 
(Hickey, et al., 2001).   
1.2.3.2 Physiological Functions 
iNOS plays an important role in numerous physiological and pathophysiological 
conditions, such as blood pressure regulation, inflammation, infection, and the onset and 
progression of malignant diseases (Lirk, et al., 2002). Overproduction of NO by iNOS has been 
implicated in various pathological processes such as septic shock, tissue damage, inflammation 
and rheumatoid arthritis. In the same way, excess generation of intracellular reactive oxygen 
species (ROS) can damage cells by lipid peroxidation and by disrupting structural proteins, 
enzymes and nucleic acids and contribute to inflammation and tissue damage. ROS generation 
contributes to oxidative stress, which is linked to numerous degenerative conditions such as 
carcinogenesis, cardiovascular disease, inflammation, and diabetes (Wolfe and Liu, 2007). 
Therefore, NO-releasing NSAIDS have been developed and they are chemically covalent 
linkage of a NO-releasing moiety to normal NSAIDS such as aspirin, flurbiprofen and naproxen 
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(Lizhi Liu, et al., 2009).  
1.2.4 Liver X Receptors (LXRs) 
1.2.4.1 Structure and Signaling Pathways 
LXRs are ligand-activated transcription factors belonging to the nuclear receptor 
superfamily (Janowski, et al., 1996). Since their discovery in 1995, two isoforms: LXRα and 
LXRβ have been identified (Seol, et al., 1995; Willy, et al., 1995). LXRα is highly expressed in 
liver, intestine, kidney, adipose tissue, and macrophages, whereas LXRβ is ubiquitously 
expressed at a lower level (Repa and Mangelsdorf, 2000). Both isoforms share almost 80% 
amino acid identity in their DBD and LBD. As a part of their structure, LXR molecule consists 
of four domains: N-terminal ligand-independent activation function (AF-1) domain, DBD 
containing two zinc fingers, hydrophobic LBD, and C-terminal ligand-dependent transactivation 
sequence (Beltowski, 2008).  
The activated LXRs form an obligated heterodimer complex with RXR and bind to LXR-
response elements (LXREs) located in the regulatory regions of LXR target genes. Following 
ligand binding, the LXR/RXR complex undergoes a conformational change that leads to the 
release of co-repressors and the recruitment of co-activators, which activates target genes 
transcription (Cannon, et al., 2016; Wiebel and Gustafsson, 1997) as seen in Figure1.6. 
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Figure 1.6 Mechanism of LXR activation. The figure was reproduced with appropriate permission from 
the Springer publishing group (Cannon, et al., 2016). 
 
1.2.4.2 Ligands and Physiological Functions 
Oxidized cholesterol derivatives (oxysterols) seem to be the major endogenous LXR 
ligands, in particular 24(S)-hydroxycholesterol, 22(R)-hydroxycholesterol, 24(S),v25-
epoxycholesterol, 27-hydroxycholesterol (Janowski, et al., 1999).  
In addition, two non-steroidal synthetic compounds, T0901317 and GW3965 have been 
identified as LXR agonists and are commonly used in experimental studies (Molteni, et al., 
2007). However, T0901317 activates both LXRα and LXRβ with an EC50 of about 20 nM 
(Schultz, et al., 2000) and it is not a specific LXR ligand since it activates also farnesoid X 
receptor (FXR) (Houck, et al., 2004), and pregnane X receptor (PXR) (Mitro, et al., 2007). Thus, 
not all effects of T0901317 observed in experimental studies can be attributed to LXR 
stimulation. On the other hand, GW3965 has a greater affinity for LXRβ than for LXRα; 
nevertheless, the difference is insufficient to differentiate between both isoforms in experimental 
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studies.  
Plant sterols such as stigmasterol, sitosterol, phytosterol, campesterol, and ergosterol 
have been reported as LXR ligands (Kaneko, et al., 2003; Plat, et al., 2005; Chendong Yang, et 
al., 2004). 
The two isoforms of LXR are regulators of lipogenesis, cholesterol/glucose homoeostasis 
and inflammatory pathways (Baranowski, 2008; Janowski, et al., 1999), processes that are 
correlated with development of MetS. For instance, studies have shown that LXR activation 
improves glucose tolerance in diabetic animal models and also protects mice from high fat diet-
induced obesity and insulin resistance (Cao, et al., 2003; Gao and Liu, 2013; Laffitte, et al., 
2003).  
Due to these beneficial effects, the employment of LXRs as molecular targets for 
management of various aspects of MetS has been recognized. Unfortunately, severe side effects, 
like hepatic steatosis and hyperlipidemia have been some of the challenges in progressing LXR 
modulators to the clinic (Chisholm, et al., 2003). For these reasons, novel drugs focused on 
development of isoform-specific or tissue-specific LXR agonist compounds are required to avoid 
effects on lipid biosynthesis and improve efficacy.  
In conclusion, due to a close association of MetS with oxidative stress and inflammatory 
processes (Wellen and Hotamisligil, 2005), there has been an increased interest in these 
molecular targets (PPARs, NF-κB, iNOS, and LXRs) (Figure 1.7) and the drugs affecting them 
are emerging as important class of therapeutic agents. 
Consequently, identification of potential bioactive molecules by exploiting the repertoire 
of natural products from the Panamanian flora was one of the aims of this investigation. 
 
 25 
 
Figure 1.7 Model of overlapping metabolic and inflammatory signaling and sensing pathways in 
adipocytes or macrophages. The figure was reproduced with appropriate permission from the American 
Society for Clinical Investigation publishing group (Wellen and Hotamisligil, 2005). 
 
1.3 Panamanian Flora 
1.3.1 Isthmus of Panama 
The Isthmus of Panama joins North and South America and forms a unique terrestrial 
bridge that divides the Atlantic and Pacific oceans, as seen in Figure 1.8. It is generally believed 
that the emergence of the isthmus occurred 3.5 million years ago but new evidence suggests that 
it was formed in a stop-and-go manner as far back as 20 million years (Bacon, et al., 2015). Due 
to its biogeographic characteristics, Panama plays an important role in the exchange of species 
between these two parts of the continent (M. P. Gupta, 1995). In addition, Panama has twelve 
different life zones, which together form an extraordinary mosaic of habitats that support a high 
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species richness and a genetic diversity. This unique land bridge has an extreme biological 
importance. In fact, throughout the isthmus, there is an amalgam of biotas of the north and the 
south that represents a vast flora and fauna diversity. This diversity is supported by a unique 
collection of environmental factors, including a tropical climate, which influence and allow the 
coexistence of many species. Therefore, its integrity as a biological bridge is necessary for the 
continued existence and evolution of the species of this important region of the planet (Mahabir 
P. Gupta, et al., 1999). 
                           
Figure 1.8 The resurgence of the Isthmus of Panama around 20 million years ago. The figure was 
reproduced with appropriate permission from the Smithsonian Tropical Research Institute. 
 
1.3.2 Panamanian Flora 
The flora of Panama is one of the richest in the neotropical area with an estimated of 
9520 vascular plant species, of which 12% are endemic (Correa, et al., 2004). Panama has over 
687 species of ferns and around 1000 species of orchids, of which 50% are endemic. Epiphytes, 
lianas, and climbers are major components of the Panamanian tropical forest. Also, there is a 
large number of nonvascular species. Panama has a higher density (number of species per 10,000 
km
2
)
 
than bigger countries like India, China, and the United States (W.  Barthlott, et al., 2014; 
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W. Barthlott, et al., 2007; W. Barthlott, et al., 1996) as shown in Figure 1.9.
 
Therefore, this 
country is one of the 25 most plant-rich countries in the world (Figure 1.10) and it is considered 
to be one of  the hot spot countries in the world with a great ecological impact (Caballero-George 
and Gupta, 2011; Correa and Valdespino, 1998). Furthermore, the tropical rainforests present in 
this area represent a rich source of biomass on Earth and are characterized by several types of 
habitats, each one with different conditions of nutrients, light intensity, humidity and 
temperature. The value of biotic richness in this tropical ecosystem is enormous (Mahabir P. 
Gupta, et al., 1999). For these reasons, the rich biodiversity and the high percentage of endemic 
species in the flora of Panama represent a reservoir of promising plant species which could be 
the source of many novel bioactive molecules or lead compounds. Consequently, there is an 
urgent need to intensify the efforts to study the untapped Panamanian flora as its potential as a 
source of new therapeutic agents has not been fully explored. 
      
Figure 1.9 Global biodiversity: Species number of vascular plants. The figure was reproduced with 
appropriate permission from Barthlott et al., 2014.  
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Figure 1.10 The 25 most plant-rich countries. The figure was reproduced with appropriate permission 
from Correa and Valdespino, 1998. 
 
1.3.3 Natural Products 
Throughout history, natural products have proven to be the richest source of novel 
compound classes with a unique and vast chemical diversity and great therapeutic potential to 
treat human diseases (Cragg, et al., 1997; Newman and Cragg, 2007; Newman, et al., 2003).
 
As 
an example, the number of new chemical entities based on natural products approved by the US 
Food and Drug Administration (FDA) in 2010, corresponded to 50%, which reveals that natural 
products continued to play an important role in the discovery and development of new 
pharmaceuticals (Newman and Cragg, 2012). Moreover, the utilization of natural products and/or 
their novel structures, in order to discover and develop the final drug entity, is still alive and well 
(Newman and Cragg, 2016). 
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It has been estimated that only 6% of the approximately 391,000 plant species worldwide 
(RBG Kew 2016) have been pharmacologically and only 15% phytochemically studied (Cragg 
and Newman, 2010). In fact, plants represent a valuable supply of new agents and a reservoir of 
novel lead compounds. 
 
Medicinal plants constitute a source of raw material for both traditional 
systems of medicine and modern medicine. Most rural populations, especially in developing 
countries, depend on medicinal herbs as their main source of primary health care (Schuster, 
2001). During the last quarter century the biomedical potential of herbal drugs used in 
Panamanian traditional medicine has been investigated and there has been an intensified effort to 
study the Panamanian flora as source of novel bioactive molecules (Caballero-George and 
Gupta, 2011)
 
. The Center for Pharmacognostic Research on Panamanian Flora (CIFLORPAN) 
at the University of Panama has played a key role in exploiting the repertoire of natural products 
from the flora of Panama.   
1.3.4 Center for Pharmacognostic Research on Panamanian Flora (CIFLORPAN) 
Systematic studies on Panamanian flora began in 1972 by Gupta and co-workers. During 
the last four decades, CIFLORPAN has carried out different research studies such as: ethno-
botanical inventories of medicinal plants used by native Amerindian groups, evaluation of 
medicinal plants used in folk medicine, biological screening of plant extracts, isolation and 
characterization of bioactive compounds, and bioprospection studies. 
This historical development has been accomplished with the collaborative efforts of 
many scientists worldwide as well as multinational projects financed by the Organization of 
American States, European Union, National Secretariat of Science, Technology and Innovation 
of Panama, International Foundation for Science, Iberoamerican Program of Science and 
 30 
Technology for Development (CYTED), and International Cooperative Biodiversity Group (M. 
P. Gupta, 2004). 
Gupta and collaborators have shown in three reviews (Caballero-George and Gupta, 
2011; M. P. Gupta, 1995; Mahabir P. Gupta, et al., 1999) that the flora of Panama is extremely 
rich in bioactive compounds and still represents an untapped source of novel bioactive 
compounds for the pharmaceutical industry. 
The results of ethno-botanical surveys carried out among three Amerindians groups: 
Guna (M. P. Gupta, et al., 1993), Guaymi or Ngäbe-Bugle (Joly, et al., 1987; Joly, et al., 1990) 
and Teribe or Nasó (M. P. Gupta, et al., 2005), reveal the widespread use of medicinal plants. 
Furthermore, these inventories allowed the establishment of the ethnomedical database 
PLANMEDIA with 4,129 entries which include: 1,159 species, 692 genera, and 167 families. 
The voucher specimens are kept at the Herbarium of the University of Panama.  
Phytochemical research on promising plants accomplished at CIFLORPAN has resulted 
in the isolation of approximately 390 compounds from 86 plants, of which 160 are new to the 
literature. These belong to very diverse compound classes: naphthoquinones, flavonoids, 
biphenyls, coumarins, acetogenins, xanthones, benzoic acid derivatives, monoterpenes, 
triterpenes, saponins, alkaloids, amides, procyanidins, quinones, amides, iridoids, tannins, 
dimeric secoiridoids, and quassinoids (Caballero-George and Gupta, 2011). This extensive 
information shows that the Panamanian flora has many potential species with interesting 
bioactivities and that much remains to be explored.  
In order to achieve the research goals of this project the interuniversity cooperation 
between the National Center for Natural Products Research (NCNPR), Department of 
BioMolecular Sciences of the University of Mississippi and CIFLORPAN of the University of 
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Panama have been crucial.  
Dr. Mahabir Gupta is the founding director of CIFLORPAN and has vast experience in 
ethnobotany, bioprospection, chemistry of natural products and drug discovery. His work has 
been characterized by multidisciplinary collaboration with many multinational cooperative 
research groups and he has promoted the training of scientists in developing countries. In 
summary, Dr. Gupta’s contribution in Panama and worldwide to the development of the regional 
flora as a source of bioactive lead compounds has been enormous and his collaboration in this 
research project is invaluable. 
In conclusion, the rich biodiversity and a high percentage of endemic species in the 
Panamanian flora offer a challenge and opportunity to discover new therapeutic agents for the 
ailments of mankind. As a proof of concept, several authenticated plant families endemic to 
Panama were selected for further phytochemical and biological investigations. Some of the plant 
families include: Araceae, Rubiaceae, Melastomataceae, and Piperaceae. 
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CHAPTER 2                                                                                                
OVERALL GOAL AND SPECIFIC AIMS 
MetS and its cluster of metabolic abnormalities have been associated with mortality. The 
increased prevalence of metabolic disorder has been connected with an increased incidence of 
cardiovascular death. In addition, numerous studies have also examined the correlation between 
the presence of MetS and the risk of T2DM. 
Therefore, new treatments are required to tackle this progressive disease. Agonists of 
PPARs represent a recognized line of therapy for the treatment of the abnormalities associated 
with MetS. In addition, the activation of NF-κB in response to pro-inflammatory signals 
contributes significantly to the progress of inflammation and subsequent development of MetS. 
On the other hand, overproduction of NO by iNOS has been implicated in numerous 
degenerative conditions such as cardiovascular disease, inflammation, and diabetes. 
Furthermore, the nuclear receptor, LXR has been considered as a significant target in treating 
metabolic diseases due to its effect on lipid metabolism and inflammatory processes. In 
summary, these four molecular targets play a remarkable role in the progression of MetS. 
Throughout history, plant derived compounds with a unique and vast chemical diversity 
have played a crucial role in drug discovery, the isolation of bioactive natural products from the 
Panamanian flora could be the starting point to address multiple risk factors related to MetS. 
As a result, the overall goal of the research conducted was based on the pharmacological 
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and phytochemical exploration of Panamanian flora and their potential effect on the molecular 
targets (PPARs, NF-κB, LXRs, and iNOS) involved in MetS.  
In order to accomplish this goal and to identify potential candidates with an ideal activity 
profile for the treatment of metabolic disorder, the following specific aims were proposed. 
Specific Aim 1 
To explore plant material from the tropical forest of Panama available in the repository of the 
National Center for Natural Products Research (NCNPR), through a material transfer agreement 
and to prepare extracts of these plant materials. 
Specific Aim 2  
To evaluate the pharmacological activity of plant extracts towards the molecular targets: PPARα, 
PPARγ, LXR, NF-κB, and iNOS which are involved in metabolic abnormalities, such as T2DM, 
hypercholesterolemia, inflammation and obesity. 
Specific Aim 3 
To isolate and characterize the secondary metabolites (bioassay-guided fractionation) with 
promising biological activities and no toxicity to mammalian cells. 
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CHAPTER 3                                                                                           
SELECTION OF PLANTS AND PREPARATION OF EXTRACTS 
3.1 Selection of Plants 
In view of the increasing need for investigating plants of the tropical forests as a 
contribution to the search for new therapeutic agents directed toward the mitigation of metabolic 
abnormalities, a collection of Panamanian plants was selected from the repository of the 
NCNPR, within the framework of international cooperation between the University of 
Mississippi and the University of Panama.  Plants were collected from the tropical forests of 
Panama, utilizing a biodiversity-based plant selection approach, as a result of the extraordinary 
accessibility of a diversity of intact forest which allowed the collections of species across large 
gradients in rainfall and altitude and across biomes with primarily Central and South American 
influences. The taxonomic identity of these plant species was established by botanical 
identification expert Prof. Mireya Correa at University of Panama and the voucher specimens 
were deposited at the Herbarium of the University of Panama, Panama. In order to conduct this 
research, the plant material was provided by Dr. Mahabir Gupta, director of CIFLORPAN, with 
more than four decades of experience in the systematic study of Panamanian flora, through a 
material transfer agreement to assure the conservation, sustainable use and access to biological 
resources.  
A total of 75 plant species belonging to 71 genera and 41 families were studied. The 
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botanical names, vernacular names, plant parts and uses are listed in Tables 3.1 and 3.2.  
Table 3.1 Panamanian plant species. 
Family / Plant Species Vernacular Name Part
Acanthaceae
Barleria oenotheroides  Dum. Cours. Twöu kirire, gusanillo
1
Leaves
Achariaceae 
Mayna odorata  Aubl. Terciopelo
2
Leaves
Adoxaceae 
Viburnum costaricanum  (Oerst.) Hemsl. Conchudo
1
Leaves
Annonaceae
Cymbopetalum lanugipetalum  Schery Stem
Apocynaceae 
Lacmellea panamensis  (Woodson) Markgr. Lagarto negro, palo perezozo
2
Bark, Stem
Odontadenia puncticulosa  (Rich.) Pulle Amali, latawira
1
Stem
Peltastes colombianus  Woodson Sin arremate
3
Leaves
Tabernaemontana panamensis  (Markgr., 
Boiteau & L. Allorge) Leeuwenb.
Rosa de lima, rosa de taboga, tabogana
3 Leaves
Araceae
Homalomena wendlandii  Schott Leaves, Rhizome
Philodendron radiatum  Schott Whole plant
Arecaceae
Bactris barronis  L.H. Bailey Uvito, caña brava
2
Leaves
Bactris gasipaes  Kunth Pixbae, pixbá, pifá, pejibaye
2
Fruit
Cryosophila warscewiczii  (H. Wendl.) Bartlett Guágara, palma escoba, noli
2
Leaves
Euterpe precatoria  Mart. Palmito, rabiahorcado
2     
Leaves, Stem
Socratea exorrhiza  (Mart.) H. Wendl. Maquengue, jira, chonta, ila, zanora, bugáda
3
Leaves
Asteraceae 
Chaptalia nutans  (L.) Pol. Pamo de sol, diente de leon, guara dogo, culantro 
blanco, pipita, amargón, sanapa'luego, pipito, 
plumerito
1,3    
Root
Elephantopus mollis  Kunth Lengua de vaca
3
Aerial parts
Lasianthaea fruticosa  (L.) K.M. Becker Leaves
Begoniaceae
Begonia urophylla  Hook. Begonia
1
Whole plant
Bignoniaceae
Callichlamys latifolia  (Rich.) K. Schum. Guirnalda amarilla
3
Leaves
Mansoa hymenaea  (DC.) A.H. Gentry Ago, hosmeca, jumeca, olmeca, pedo de padre
3   
Leaves
Bixaceae
Bixa orellana  L. Achiote, misar, nisar, haru, bija, anatto, achote, kuró
3   
Stem
Burseraceae
Bursera simaruba  (L.) Sarg. Almácigo, carate, indio desnudo, cholo pelao, indio en 
cuera
2
Bark
Protium glabrum  (Rose) Engl. Copal, copá, chutra, kerosín, alcanfor
2
Stem
Trattinnickia aspera  (Standl.) Swart Caraño, caraño hediondo
2       
Leaves
continued  
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Table 3.1 Continued 
Family / Plant Species Vernacular Name Part
Calophyllaceae
Calophyllum longifolium  Willd. María, santa maría, calaba
2    
Branch, Leaves
Clusiaceae
Clusia rosea  Jacq. Copé, copey
2    
Fruit
Garcinia madruno  (Kunth) Hammel Fruta de mono, satra, satro, machari, cero, mudguia, 
tomé, cerillo
3        
Leaves
Combretaceae
Terminalia amazonia  (J.F. Gmel.) Exell Roble amarillo, amarillo carabazuelo, palo amarillo, 
nargusta, guayabo de montaña, guayabillo blanco, 
carboncillo, calbazue
3
Branch
Commelinaceae
Tripogandra serrulata  (Vahl) Handlos Kuck tan, rodillera
1
Whole plant
Costaceae
Costus pulverulentus  C. Presl Leaves
Cucurbitaceae
Psiguria warscewiczii  (Hook. f.) Wunderlin Ni murei odochi
1
Aerial parts
Dichapetalaceae
Dichapetalum axillare  Woodson Leaves, Stem
Dilleniaceae
Davilla kunthii  A. St.-Hil. Chumiquillo, chumico peorro, chumico pedorro, 
chumico, chumico bijuco
3
Leaves
Gentianaceae
Lisianthius peduncularis  L.O. Williams Leaves
Gesneriaceae
Chrysothemis friedrichsthaliana  (Hanst.) H.E. 
Moore
Wilkwa, ceodotaona, cuibad
3 Root
Columnea nicaraguensis  Oerst. Leaves
Solenophora calycosa  Donn. Sm. Leaves
Heliconiaceae 
Heliconia hirsuta  L. f. San juanillo, mülengöi, chichica
3
Root
Malvaceae
Guazuma ulmifolia  Lam. Guácimo, cabeza de negrito
2
Bark
Luehea seemannii  Triana & Planch. Guácimo colorado, guácimo molenillo, guácimo 
pacheco
2    
Leaves
Melochia spicata  (L.) Fryxell Hierba del soldado
3
Aerial parts
Ochroma pyramidale  (Cav. ex Lam.) Urb. Puero, lana, cotton tree, balso, abogado, krung
3
Leaves
Quararibea pterocalyx  Hemsl. Guayabillo
2
Leaves
Trichospermum galeottii  (Turcz.) Kosterm. Majaguillo de monte, capulín, majaguillo, burrilico
2                  
Leaves
continued  
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Table 3.1 Continued 
Family / Plant Species Vernacular Name Part
Melastomataceae
Clidemia ombrophila  Gleason Branch
Henriettella tuberculosa  Donn. Sm. Leaves
Miconia affinis  DC. Canillo
2
Leaves
Ossaea quinquenervia  (Mill.) Cogn. Fruta de pava
3
Leaves
Meliaceae
Trichilia havanensis  Jacq. Cacho de chivo
3
Leaves
Trichilia pallida  Sw. Terciopelo, conejito colorado
2
Leaves
Moraceae
Ficus colubrinae Standl. Higuerón, matapalo
2    
Stem
Olacaceae 
Heisteria acuminata  (Humb. & Bonpl.) Engl. Sombrerito, ajicillo, chorola, consuelo
2
Leaves
Phytolaccaceae
Petiveria alliacea  L. Urgat, garlic weed, anamú, anamo, ocaño, zorrillo, 
kuan
3       
Leaves
Piperaceae
Piper friedrichsthalii  C. DC. Leaves
Piper hispidum  Sw. Bacher
4
Leaves
Primulaceae
Clavija costaricana  Pittier Wohoa dwroyo
5
Leaves
Rubiaceae
Bathysa veraguensis  Dwyer Stem
Chiococca alba  (L.) Hitchc. Lágrimas de maría, lágrimas
3
Leaves
Coussarea curvigemmia  Dwyer Huesito
2
Bark, Leaves
Coutarea hexandra  (Jacq.) K. Schum. Quina, piregueta, niño muerto, azulejo
3
Flower
Pentagonia nuciformis  Dwyer Leaves, Stem
Psychotria chagrensis  Standl. Psicotria de chagres
3
Stem
Psychotria orosiana  Standl. Leaves
Warszewiczia coccinea  (Vahl) Klotzsch Sanguinaria, cresta de gallo, orinera, orín, guna
2
Leaves
Salicaceae 
Xylosma chlorantha  Donn. Sm. Cachos de venado
2
Leaves
Sapindaceae 
Billia hippocastanum  Peyr. Leaves
Talisia nervosa  Radlk. Mamón de montaña, mamón de monte
2
Leaves, Stem
Simaroubaceae
Simaba cedron  Planch. Cedrón, ina gaibid, cedrion
3      
Leaves
continued  
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Table 3.1 Continued 
Family / Plant Species Vernacular Name Part
Siparunaceae
Siparuna guianensis  Aubl. Pasmo hediondo, pasmo, limoncillo, hierba de pasmo
3 Fruit
Solanaceae
Cestrum latifolium  Lam. Juan de la verdad
3
Leaves
Stemonuraceae
Discophora guianensis  Miers Leaves
Verbenaceae
Petrea volubilis  L. Viuda, topopostillo, soltero, raspa-sombrero, purple-
wreath, hoja chigüe, flor de santa maría, flor de jesús
3
Stem
Violaceae 
Hybanthus denticulatus  H.E. Ballard, Wetter & 
N. Zamora
Leaves
Zingiberaceae
Renealmia cernua  (Sw. ex Roem. & Schult.) J.F. 
Macbr.
Root
1 
CIFLORPAN Database (University of Panama)
2 
Trees, Shrubs, and Palms of Panama, Center for Tropical Forest Science. http://ctfs.arnarb.harvard.edu/webatlas/maintreeatlas.php
3 
Herbario Universidad de Panamá. http://herbario.up.ac.pa/Herbario/herb/vasculares/ 
4 
Gupta, M.P.; Correa, M.D.; Solís, P.N.; Jones, A.; Galdames, C.; Guionneau-Sinclair, F. Medicinal Plant Inventory of Kuna Indians: 
  Part I. J Ethnopharmacol.  1993, 40 , 77-109.
5 
Gupta, M.P.; Solís, P.N.; Calderón, A.I.; Guionneau-Sinclair, F.; Correa, M.; Galdames, C.; Guerra, C.; Espinosa, A.; Alvenda, G.I.;
  Robles, G.; Ocampo, R. Medical Ethnobotany of the Teribes of Bocas del Toro, Panama. J Ethnopharmacol. 2005, 96 , 389-401.  
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Table 3.2 Panamanian plant species: Uses. 
Family / Plant Species Use Part
Acanthaceae
Barleria oenotheroides  Dum. Cours. Leaves
Achariaceae 
Mayna odorata  Aubl. Leaves
Adoxaceae 
Viburnum costaricanum  (Oerst.) Hemsl. Leaves
Annonaceae
Cymbopetalum lanugipetalum  Schery Stem
Apocynaceae 
Lacmellea panamensis  (Woodson) Markgr. Vaginal thrush, increase milk flow in breastfeeding
1
Bark, Stem
Odontadenia puncticulosa  (Rich.) Pulle Rubella
2
Stem
Peltastes colombianus  Woodson Diarrhea
2
Leaves
Tabernaemontana panamensis  (Markgr., Boiteau & 
L. Allorge) Leeuwenb.
Leaves
Araceae
Homalomena wendlandii  Schott Snakebite
3
Leaves, Rhizome
Philodendron radiatum  Schott Pain, snakebite
3
Whole plant
Arecaceae
Bactris barronis  L.H. Bailey Leaves
Bactris gasipaes  Kunth Edible
4
Fruit
Cryosophila warscewiczii  (H. Wendl.) Bartlett Leaves
Euterpe precatoria  Mart. Edible
4
Leaves, Stem
Socratea exorrhiza  (Mart.) H. Wendl. Leaves
Asteraceae 
Chaptalia nutans  (L.) Pol. Muscular pain, intestinal worms, ulcers
5
Root
Elephantopus mollis  Kunth Aerial parts
Lasianthaea fruticosa  (L.) K.M. Becker Leaves
Begoniaceae
Begonia urophylla  Hook. Furuncles
6
Whole plant
Bignoniaceae
Callichlamys latifolia  (Rich.) K. Schum. Body aches, loss of appetite
7
Leaves
Mansoa hymenaea  (DC.) A.H. Gentry Leaves
Bixaceae
Bixa orellana  L. Insect repellent
1
Stem
Burseraceae
Bursera simaruba  (L.) Sarg. Urinary infections, bruises, contraceptive
3
Bark
Protium glabrum  (Rose) Engl. Colds, asthma, headaches
4
Stem
Trattinnickia aspera  (Standl.) Swart Depurative, hypertension, leishmaniasis
3
Leaves
Calophyllaceae
Calophyllum longifolium  Willd. Heal wounds
1
Branch, Leaves
Clusiaceae
Clusia rosea  Jacq. Fruit
Garcinia madruno  (Kunth) Hammel Edible
4
Leaves
Combretaceae
Terminalia amazonia  (J.F. Gmel.) Exell Apiculture
1
Branch
continued  
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Table 3.2 Continued 
Family / Plant Species Use Part
Commelinaceae
Tripogandra serrulata  (Vahl) Handlos Inflammation, fractures
3
Whole plant
Costaceae
Costus pulverulentus  C. Presl Pain after childbirth
7
Leaves
Cucurbitaceae
Psiguria warscewiczii  (Hook. f.) Wunderlin Shortness of breath
6
Aerial parts
Dichapetalaceae
Dichapetalum axillare  Woodson Leaves, Stem
Dilleniaceae
Davilla kunthii  A. St.-Hil. Colic in children
8
Leaves
Gentianaceae
Lisianthius peduncularis  L.O. Williams Leaves
Gesneriaceae
Chrysothemis friedrichsthaliana  (Hanst.) H.E. 
Moore
Muscle aches, inflammation of the joints, snakebite
8 Root
Columnea nicaraguensis  Oerst. Fever
3
Leaves
Solenophora calycosa  Donn. Sm. Leaves
Heliconiaceae 
Heliconia hirsuta  L. f. Antidiarrhoeic
7
Root
Malvaceae
Guazuma ulmifolia  Lam. Cardiovascular disorders
9
Bark
Luehea seemannii Triana & Planch. Apiculture
1
Leaves
Melochia spicata  (L.) Fryxell Aerial parts
Ochroma pyramidale  (Cav. ex Lam.) Urb. Leaves
Quararibea pterocalyx  Hemsl. Edible
4
Leaves
Trichospermum galeottii  (Turcz.) Kosterm. Apiculture
1
Leaves
Melastomataceae
Clidemia ombrophila  Gleason Branch
Henriettella tuberculosa  Donn. Sm. Leaves
Miconia affinis  DC. Leaves
Ossaea quinquenervia  (Mill.) Cogn. Fever
3
Leaves
Meliaceae
Trichilia havanensis  Jacq. Leaves
Trichilia pallida  Sw. Leaves
Moraceae
Ficus colubrinae Standl. Stem
Olacaceae 
Heisteria acuminata  (Humb. & Bonpl.) Engl. Leaves
Phytolaccaceae
Petiveria alliacea  L. Ritual ceremonies
7
Leaves
Piperaceae
Piper friedrichsthalii  C. DC. Leaves
Piper hispidum  Sw. Fever
3
Leaves
Primulaceae
Clavija costaricana  Pittier Expel worms
3
Leaves
continued  
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Table 3.2 Continued 
Family / Plant Species Use Part
Rubiaceae
Bathysa veraguensis  Dwyer Stem
Chiococca alba  (L.) Hitchc. Groin inflammation, antivenereal, emmenagogue
5
Leaves
Coussarea curvigemmia  Dwyer Bark, Leaves
Coutarea hexandra  (Jacq.) K. Schum. Fever, inflammation, stomach pain
4
Flower
Pentagonia nuciformis  Dwyer Leaves, Stem
Psychotria chagrensis  Standl. Stem
Psychotria orosiana  Standl. Leaves
Warszewiczia coccinea  (Vahl) Klotzsch Aphrodisiac, bladder inflammation
4
Leaves
Salicaceae 
Xylosma chlorantha  Donn. Sm. Leaves
Sapindaceae 
     Billia hippocastanum  Peyr. Leaves
Talisia nervosa  Radlk. Edible
10
Leaves, Stem
Simaroubaceae
Simaba cedron  Planch. Fever, malaria, snakebite
7
Leaves
Siparunaceae
Siparuna guianensis  Aubl. Spasm, headache
4
Fruit
Solanaceae
Cestrum latifolium  Lam. Leaves
Stemonuraceae
Discophora guianensis  Miers Fever
4
Leaves
Verbenaceae
Petrea volubilis  L. Stem
Violaceae 
Hybanthus denticulatus  H.E. Ballard, Wetter & N. 
Zamora
Leaves
Zingiberaceae
Renealmia cernua  (Sw. ex Roem. & Schult.) J.F. 
Macbr.
Root
1 
Ibáñez, A.; Castroviejo, S.; Fernández, J.L.; Correa, M.D. Catalogue of the Flora of the Bahía Honda Region (Veraguas, Panama). 
  Consejo Superior de Investigaciones Científicas. 2005;  pp 177. 
2 
Caballero-George, C.; Gupta, M.P. A Quarter Century of Pharmacognostic Research on Panamanian Flora: A review.  Planta Med.
  2011, 77 , 1189-1202.
3 
Gupta, M.P.; Solís, P.N.; Calderón, A.I.; Guionneau-Sinclair, F.; Correa, M.; Galdames, C.; Guerra, C.; Espinosa, A.; Alvenda, G.I.;
  Robles, G.; Ocampo, R. Medical Ethnobotany of the Teribes of Bocas del Toro, Panama. J Ethnopharmacol. 2005, 96 , 389-401.
4 
Trees, Shrubs, and Palms of Panama, Center for Tropical Forest Science. http://ctfs.arnarb.harvard.edu/webatlas/maintreeatlas.php
5 
Gupta, M.P. 270 Plantas Medicinales Iberoamericanas. CYTED-SECAB. Santafe de Bogota, D.C. Colombia. 1995; pp 617.
6 
Joly, L.G.; Guerra, S.; Séptimo, R.; Solís, P.N.; Correa, M.D.; Gupta, M.P.; Levy, S.; Sandberg F.; Perera, P. Ethnobotanical Inventory 
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3.2 Preparation of Plant Extracts 
The dried powder of each plant material (10 g) was extracted in a semi-automated 
process using a Dionex accelerated solvent extractor (ASE200) system. Briefly, the sample was 
contained within a cell that was filled with 25 mL of 95% ethanol at 1500 psi and 40°C for 10 
min. The extract was then flushed from the cell with an equal volume of 95% ethanol. The 
solvent was evaporated using a combination of rotary evaporation and vacuum centrifugation to 
give dried ethanolic extract. The residue was dissolved in DMSO (20 mg/mL) and used as test 
sample for biological activity evaluation. 
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CHAPTER 4                                                                                     
EVALUATION OF BIOLOGICAL ACTIVITY 
4.1 PPARα and PPARγ Activation 
4.1.1 General Experimental Procedures 
Reporter genes have become an invaluable tool in studies of gene expression. They are 
widely used in biomedical and pharmaceutical research and also in molecular biology and 
biochemistry. A gene consists of two functional parts: one is a DNA sequence that gives the 
information about the protein that is produced (coding region); the other part is a specific DNA 
sequence linked to the coding region, which regulates the transcription of the gene (promoter). 
The promoter is either activating or suppressing the expression of the target gene. The purpose of 
the reporter gene assay is to measure the regulatory potential of an unknown sequence. This can 
be done by linking a promoter sequence to an easily detectable reporter gene such as that 
encoding for the firefly luciferase. Various detection methods are used to measure expressed 
reporter gene protein. For the purpose of this research, we used luminescence. The advantages of 
a luciferase assay are high sensitivity, the absence of luciferase activity inside most of the cell 
types and the wide dynamic range and low costs.   
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4.1.1.1 Reporter Gene Assay for Determining PPARs Transcriptional Activity 
Human hepatoma (HepG2) cells were obtained from the American Type Culture 
Collection (ATCC HB-8065) (Rockville, MD) and cultured in Dulbecco's Modified Eagle's 
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Hyclone, South Logan, 
UT), 100 units/mL penicillin and 100 g/mL streptomycin (Gibco, Grand Island, NY) in a 
humidified atmosphere of 5% CO2 at 37°C. Cell-based reporter gene assay for the identification 
of PPARα and PPAR agonists was carried out following the method described previously with 
some modification (Min Hye Yang, et al., 2013; Zhao, et al., 2014). HepG2 cells were 
transfected with either pSG5-PPARα (plasmid 22751) and PPRE X3-tk-luc (plasmid 1015) 
obtained from Addgene (Cambridge, MA) or pCMV-rPPAR and pPPREaP2-tk-luc obtained 
from Dr. Dennis Feller (Department of Pharmacology, University of Mississippi) plasmid DNA 
(25 g of each/1.5 mL cell suspension) by electroporation at 160 V for single 70 msec pulse 
using BTX disposable cuvette with a Square electroporator T820 (BTX, San Diego, CA). 
Transfected cells were plated at a density of 5  104 cells/well in 96-well tissue culture plates and 
grown for 24 h. After 24 h, the cells were treated with plant extracts or pure compounds (25, 50 
and 100 g/mL) or ciprofibrate or ciglitazone (3, 10, 30 M) (Cayman Chemical, Ann Arbor, 
MI). After incubation for 24 h, the cells were lysed by adding 40 L of a 1:1 mixture of 
luciferase assay system (Promega, Madison, WI) and PBS containing 1 mM calcium and 
magnesium. Light output was detected on a SpectraMax M5 plate reader (Molecular Devices, 
Sunnyvale, CA). Plant extracts showing a 2-fold activation or more were considered active.  
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4.1.1.2 Cytotoxicity to HepG2 Cells 
The effect of plant extracts on the viability of HepG2 cells was evaluated by the Neutral 
Red (Sigma-Aldrich, St Louis, MO) colorimetric method (Borenfreund, et al., 1990). The cells 
were seeded in 96-well tissue culture-treated plates at a density of 25,000 cells/well. After 24 h, 
plant extracts were added at different concentrations and cells were further incubated for 48 h. 
The medium was removed and 100 L of neutral red solution (1 mg/mL) was added to each well 
and the plates were incubated at 37°C under 5% of CO2 for 90 min. Cells were subsequently 
washed with warm saline and the dye was dissolved by adding 100 L of 0.33% hydrochloric 
acid in isopropanol. The absorbance was measured at dual wavelength 490/630 nm using an EL 
312e plate reader (Bio-Tek Instruments, Winooski, VT). Cell viability was calculated in 
comparison to vehicle control. 
4.1.2 Results and Discussion 
Seventy-five plant species were studied following a biodiversity-based plant selection 
approach. Some of these plants represent endemic species in the Panamanian flora and they have 
been traditionally used by the main Amerindians groups (Guna, Guaymi, and Teribe) located in 
the Panamanian territory, as shown in Table 3.2. Thirty-one percent of plants tested for 
biological activities towards the targets related to MetS belong to the major families such as 
Rubiaceaea (11%), Malvaceae (8%), Arecaceae (7%), Apocynaceae (5%), and Melastomataceae 
(5%), as seen in Figure 4.1. Dried plant parts were extracted with 95% ethanol to give 83 
extracts. In a first stage, the 83 ethanolic plant extracts were subjected to screening their 
agonistic effect on PPARα and PPARγ transcriptional activity in a concentration range of 25-100 
g/mL. The extracts of 22 plants were found to activate PPARα while fifteen extracts activated 
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PPARγ with a 2-fold activation over the vehicle control, as shown in Tables 4.1 and 4.2. 
In addition, the extracts of eleven plants: Bixa orellana, Bursera simaruba, Chaptalia 
nutans, Columnea nicaraguensis, Elephantopus mollis, Ficus colubrinae, Garcinia madruno, 
Homalomena wendlandii, Tabernaemontana panamensis, Talisia nervosa, and Viburnum 
costaricanum exhibited dual activation of PPARα and PPARγ. Out of these three plants: Bursera 
simaruba, Chaptalia nutans, and Talisia nervosa were highly effective with a fold activation of 
4.85, 4.29, 5.25 for PPARα and 6.59, 4.57, 9.52 for PPARγ at a concentration of 100 g/mL. 
In the same way, positive controls ciprofibrate and ciglitazone activated PPARα and 
PPARγ to 3.09 ± 0.45 and 5.88 ± 0.31-fold of the vehicle control at a concentration of 30 M, 
respectively.   
In a second stage, the cytotoxicity of the extracts against HepG2 cells was also evaluated. 
Most of the extracts did not affect the viability of HepG2 cells during the 48 h incubation period 
and were not considered cytotoxic. Nevertheless, the extracts of Garcinia madruno and Piper 
friedrichsthalii decreased cell viability to 47.5% and 33.6% at a concentration of 100 g/mL, 
respectively. As a result, these two plant extracts showed higher activation of PPARα at 25 
g/mL (3.89, 4.87-fold) compared with the concentration at 100 g/mL (2.56, 2.62-fold) due to 
some signs of cytotoxicity against HepG2 cells.  
In summary, the plants that showed dual modulation of PPARα and PPARγ might have a 
potential to be novel therapeutic agents targeting the array of metabolic abnormalities. Therefore, 
these highly effective plants acting on these PPAR isoforms and without evidence of cytotoxicity 
served as a basis for the selection of the most promising extracts. Likewise, this is the first report 
of PPAR agonistic effect of these plants. 
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Plant Families
Acanthaceae Achariaceae Adoxaceae Annonaceae Apocynaceae Araceae
Arecaceae Asteraceae Begoniaceae Bignoniaceae Bixaceae Burseraceae
Calophyllaceae Clusiaceae Combretaceae Commelinaceae Costaceae Cucurbitaceae
Dichapetalaceae Dilleniaceae Gentianaceae Gesneriaceae Heliconiaceae Malvaceae
Melastomataceae Meliaceae Moraceae Olacaceae Phytolaccaceae Piperaceae
Primulaceae Rubiaceae Salicaceae Sapindaceae Simaroubaceae Siparunaceae
Solanaceae Stemonuraceae Verbenaceae Violaceae Zingiberaceae
 
Figure 4.1 Analysis and distribution of plant families subjected to the evaluation of PPARα and PPARγ 
transcriptional activity. 
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Table 4.1 Activation of PPARα in HepG2 cells by Panamanian plant extracts. 
Family / Plant Species Part Cell viability (%)
100 µg/mL 50 µg/mL 25 µg/mL 100 µg/mL
Adoxaceae 
Viburnum costaricanum  (Oerst.) Hemsl. Leaves 2.32 ± 0.60 2.45 ± 0.38 2.06 ± 0.22 135.3
Apocynaceae 
Odontadenia puncticulosa  (Rich.) Pulle Stem 3.70 ± 0.26 3.23 ± 0.17 2.56 ± 0.57 152.9
Tabernaemontana panamensis  (Markgr., 
Boiteau & L. Allorge) Leeuwenb. 
Leaves 2.93 ± 0.07 2.91 ± 0.26 2.72 ± 0.48 128.0
Araceae
Homalomena wendlandii Schott Leaves 2.35 ± 0.32 2.03 ± 0.40 1.52 ± 0.41 94.7
Philodendron radiatum  Schott Whole plant 2.46 ± 0.14 2.29 ± 0.35 2.16 ± 0.31 70.7
Asteraceae 
Chaptalia nutans  (L.) Pol. Root 4.29 ± 0.77 3.33 ± 0.55 1.98 ± 0.29 120.0
Elephantopus mollis  Kunth Aerial parts 4.36 ± 0.40 2.14 ± 0.16 3.12 ± 0.36 96.2
Bixaceae
Bixa orellana  L. Stem 2.14 ± 0.55 2.36 ± 0.37 1.88 ± 0.35 100.8
Burseraceae
Bursera simaruba  (L.) Sarg. Bark 4.85 ± 0.58 4.59 ± 0.29 1.20 ± 0.22 89.1
Trattinnickia aspera  (Standl.) Swart Leaves 3.45 ± 0.34 2.71 ± 0.90 1.62 ± 0.18 112.3
Calophyllaceae
Calophyllum longifolium  Willd. Leaves 3.32 ± 0.15 1.82 ± 0.69 2.10 ± 0.85 61.2
Clusiaceae
Garcinia madruno  (Kunth) Hammel Leaves 2.56 ± 0.20 4.84 ± 1.14 3.89 ± 0.95 47.5
Gesneriaceae 
Chrysothemis friedrichsthaliana  (Hanst.) 
H.E. Moore
Root 2.54 ± 0.44 1.88 ± 0.32 1.62 ± 0.51 52.4
Columnea nicaraguensis  Oerst. Leaves 3.39 ± 0.39 2.31 ± 0.25 1.99 ± 0.21 65.5
Solenophora calycosa  Donn. Sm. Leaves 3.87 ± 0.50 2.27 ± 0.48 1.20 ± 0.14 107.7
Moraceae
Ficus colubrinae  Standl. Stem 2.77 ± 0.64 2.56 ± 0.55 1.77 ± 0.49 66.2
Piperaceae 
Piper friedrichsthalii  C. DC. Leaves 2.62 ± 0.37 1.91 ± 0.55 4.87 ± 0.66 33.6
Rubiaceae
Coutarea hexandra  (Jacq.) K. Schum. Flower 5.73 ± 0.76 5.57 ± 0.39 0.71 ± 0.09 119.5
Pentagonia nuciformis  Dwyer Leaves 4.53 ± 0.27 2.37 ± 0.61 2.03 ± 0.24 92.9
Warszewiczia coccinea  (Vahl) Klotzsch Leaves 1.99 ± 0.16 2.41 ± 0.41 2.12 ± 0.32 81.1
Sapindaceae 
Talisia nervosa  Radlk. Stem 5.25 ± 0.12 2.34 ± 0.49 2.51 ± 0.67 90.8
Siparuna guianensis  Aubl. Fruit 4.31 ± 0.42 2.56 ± 0.18 1.98 ± 0.36 77.8
30 μM 10 μM 3 μM
Ciprofibarte 3.09 ± 0.45 2.50 ± 0.35 2.36 ± 0.22
          PPARα (Fold Activation)  
 
 
 
 49 
Table 4.2 Activation of PPARγ in HepG2 cells by Panamanian plant extracts. 
Family / Plant Species Part Cell viability (%)
100 µg/mL 50 µg/mL 25 µg/mL 100 µg/mL
Achariaceae 
Mayna odorata  Aubl. Leaves 2.62 ± 0.11 2.10 ± 0.07 1.96 ± 0.24 103.3
Adoxaceae 
Viburnum costaricanum  (Oerst.) Hemsl. Leaves 5.24 ± 0.31 4.95 ± 0.15 1.16 ± 0.04 135.3
Apocynaceae 
Tabernaemontana panamensis  (Markgr., 
Boiteau & L. Allorge) Leeuwenb. 
Leaves 2.39 ± 0.50 1.82 ± 0.09 1.75 ± 0.36 128.0
Araceae
Homalomena wendlandii  Schott Leaves 3.13 ± 0.48 2.14 ± 0.16 1.39 ± 0.02 94.7
Asteraceae 
Chaptalia nutans  (L.) Pol. Root 4.57 ± 0.44 2.49 ± 0.28 1.87 ± 0.15 120.0
Elephantopus mollis  Kunth Aerial parts 1.96 ± 0.08 1.90 ± 0.09 1.82 ± 0.15 96.2
Bixaceae
Bixa orellana  L. Stem 4.65 ± 0.46 2.83 ± 0.07 2.58 ± 0.23 100.8
Burseraceae
Bursera simaruba  (L.) Sarg. Bark 6.59 ± 0.70 5.66 ± 0.74 2.71 ± 0.46 89.1
Clusiaceae
Garcinia madruno  (Kunth) Hammel Leaves 3.65 ± 0.27 3.41 ± 0.10 3.23 ± 0.10 47.5
Gesneriaceae
Columnea nicaraguensis  Oerst. Leaves 2.28 ± 0.24 1.85 ± 0.18 1.58 ± 0.13 65.5
Moraceae
Ficus colubrinae  Standl. Stem 3.64 ± 0.41 3.51 ± 0.44 2.56 ± 0.10 66.2
Rubiaceae
Pentagonia nuciformis  Dwyer Stem 2.56 ± 0.09 2.51 ± 0.16 1.79 ± 0.70 117.9
Salicaceae 
Xylosma chlorantha  Donn. Sm. Leaves 5.07 ± 0.17 4.82 ± 0.35 3.59 ± 0.42 56.0
Sapindaceae 
Talisia nervosa  Radlk. Leaves 5.76 ± 0.40 2.51 ± 0.14 2.18 ± 0.02 42.8
Talisia nervosa  Radlk. Stem 9.52 ± 0.64 2.02 ± 0.42 1.84 ± 0.17 90.8
30 μM 10 μM 3 μM
Ciglitazone 5.88 ± 0.31 4.10 ± 0.24 2.46 ± 0.07
 PPARγ (Fold Activation)
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4.2 Glucose Uptake  
4.2.1 General Experimental Procedures 
The glucose uptake assay was carried out in HepG2 cells by flow cytometric analysis as 
previously described with slight modification (Quan Cheng Chen, et al., 2010; Wang, et al., 
2011). Briefly, HepG2 cells were seeded in 6-well plates at a density of 2 × 10
5
 cells/well and 
incubated for 24 h. The effects of plant extracts on 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) 
amino]-2-deoxy-D-glucose (2-NBDG) (Cayman Chemical, Ann Arbor, MI) uptake were 
measured by treating the cells with the samples (50 μg/mL) together with insulin (100 nM) 
(Sigma-Aldrich, St Louis, MO) and 10 μM of 2-NBDG in glucose- and serum-free DMEM. 
After incubation for 24 h, the medium was removed and washed twice with pre-cooled 
phosphate-buffered saline (PBS) (Hyclone, South Logan, UT). Cells were scraped out in 1 mL of 
PBS and transferred into 5 mL polystyrene round-bottom tubes (BD Falcon) and kept at 4 °C for 
subsequent flow cytometric analysis. Fluorescence intensity of 2-NBDG was recorded in the FL1 
channel using a FACS Calibur flow cytometer (BD Bioscience, San Jose, CA). Data from 10,000 
single cell events were collected. Values of relative fluorescence intensity (FI) were calculated 
as: 
FI = FI2-NBDG – FIbackground 
where FI2-NBDG is the fluorescence intensity of a single cell in the presence of 2-NBDG and 
FIbackground is the fluorescence intensity in the absence of 2-NBDG. 
4.2.2 Results and Discussion   
In order to determine whether plant extracts activating both PPARα and PPARγ directly 
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affect glucose uptake, their effect on 2-NBDG uptake was studied in HepG2 cells. This HepG2 
cell line is often employed to elucidate the glucose transport activity due to the similarity of its 
physiological function and glucose metabolism to normal hepatocytes (Jinsheng Xu, et al., 
2003). 
All eleven plants (Bixa orellana, Bursera simaruba, Chaptalia nutans, Columnea 
nicaraguensis, Elephantopus mollis, Ficus colubrinae, Garcinia madruno, Homalomena 
wendlandii, Tabernaemontana panamensis, Talisia nervosa, and Viburnum costaricanum) which 
caused a significant increase in PPARα and PPARγ signaling and gene expression, were chosen 
to evaluate their effects on glucose uptake in insulin-stimulated HepG2 cells. Since, this dual 
activation influences lipid partitioning in the liver and adipocytes, resulting in improved glucose 
utilization. 
As shown in Figure 4.2, the insulin-stimulated glucose uptake into HepG2 cells tended to 
be higher in cells treated with Talisia nervosa followed by Columnea nicaraguensis, and 
Homalomena wendlandii (50 μg/mL). Rosiglitazone (10 μM), used as a positive control, caused 
an increase of 2.0 fold in the glucose uptake (Table 4.3). The relative fluorescence intensity of 
HepG2 cells treated with Talisia nervosa, Columnea nicaraguensis, and Homalomena 
wendlandii increased to 24.8, 14.1, and 13.4, respectively, as a result of an increased glucose 
uptake (3.7, 2.1, and 2.0- fold, respectively) as seen in Table 4.3.  
Furthermore, the extract of Bixa orellana showed 1.8-fold increase in glucose uptake. In 
fact, studies in vivo revealed that extracts from this plant can have either hypoglycaemic or 
hyperglycaemic activity, in addition to a hypolipidaemic effect, depending on how the extract is 
prepared (Giovannini, et al., 2016). However, there has not been report related to its effects on 
PPARα/γ and glucose uptake stimulation.  
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Table 4.3 Effect of selected plant extracts, with PPARα/γ agonistic property, on insulin-stimulated 
glucose uptake in HepG2 cells. 
Plant Species Part  Realative fluorescence intensity (FI)  Fold increase 
Control 6.7 ± 0.8
Bixa orellana L. Stem 12.1 ± 1.0 1.8
Talisia nervosa Radlk. Stem 12.0 ± 2.5 1.8
Homalomena wendlandii Schott Leaves 13.4 ± 1.5 2.0
Talisia nervosa Radlk. Leaves 24.8 ± 0.2 3.7
Columnea nicaraguensis  Oerst. Leaves 14.1 ± 0.8 2.1
Rosiglitazone (10 μM) 13.5 ± 1.1 2.0  
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Figure 4.2 Measurement of glucose uptake by flow cytometry in HepG2 cells. Cells were seeded in 6-
well plates and treated with 100 nM insulin and 10 μM 2-NBDG in the presence or absence of extract (50 
μg/mL) for 24 h. After incubation, cells were washed with PBS and 2-NBDG uptake was measured by a 
flow cytometer. (A) control, (B) 10 μM rosiglitazone, (C) B. orellana, (D) T. nervosa (stem), (E) H. 
wendlandii, (F) T. nervosa (leaves) and (G) C. nicaraguensis. 
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4.3 Adipocyte Differentiation  
4.3.1 General Experimental Procedures 
Mouse embryo preadipocyte (3T3-L1) cells were obtained from ATCC (ATCC CL-173) 
and cultured in DMEM containing 10% bovine calf serum (BCS) (Hyclone, South Logan, UT), 
100 units/mL penicillin and 100 μg/mL streptomycin at 37°C in a humidified 5% CO2 incubator. 
For the differentiation assay, preadipocytes were seeded in 48-well plates at a density of 2 x 10
4
 
cells/well and maintained until 2 days post-confluence. After 2 days of confluence (day 0), 
medium was replaced with DMEM containing 10% FBS, 10 μg/mL insulin, 1 μM 
dexamethasone (Sigma-Aldrich, St Louis, MO) and plant extracts at various concentrations (5, 
25 and 50 μg/mL) or positive control rosiglitazone (3 μM) (Sigma-Aldrich, St Louis, MO). After 
2 days, the medium was replaced with DMEM containing 10% FBS, 10 μg/mL insulin and test 
samples (day 4). Cells were then maintained in10% FBS/ DMEM for an additional 4 days (day 
8). Extent of adipogenesis was determined in differentiated adipocytes by quantification of lipid 
content and oil red O staining. 
4.3.1.1 Quantification of Lipid Content in 3T3-L1 Cells 
Lipid content was estimated with AdipoRed assay kit (Lonza, Walkersville, MD) 
according to the manufactureʼs protocol. AdipoRed is a Nile Red fluorescent reagent that enables 
the quantification of intracellular lipids from terminally differentiated adipocytes. On day 8 after 
differentiation in the presence of samples as described above, cells were carefully rinsed with 
400 μL PBS. A volume of 400 μL PBS and 12 μL AdipoRed reagent was added to each well and 
the cells were incubated at 37°C for 10 min. The fluorescent intensity was measured in a 
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SpectraMax M5 plate reader with excitation at 485nm and emission at 572 nm. The percent lipid 
content of cells was calculated compared to the vehicle control. 
4.3.1.2 Oil red O Staining 
In order to visualize the morphological changes, differentiated adipocytes were stained 
with Oil red O as previously described with some modifications (Kasturi and Joshi, 1982). 
Differentiated 3T3-L1 cells were rinsed twice with PBS and fixed with 70% ethanol for 30 min. 
The fixed cells were stained with Oil Red O solution (0.6% Oil Red O in isopropanol : water = 
3:2) for 1 h at room temperature and washed twice with distilled water. The images of stained 
cells were captured by a Nikon DS-Ri1 camera attached to an Olympus IX50 microscope 
(Olympus, Tokyo, Japan). 
4.3.2 Results and Discussion 
Adipose tissue plays a central role in whole-body energy metabolism, and defects in its 
function can lead to severe metabolic abnormalities. In fact, adipose tissue differentiation is a 
complex process regulated by two adipogenic transcription factor families including PPARγ and 
CCAAT-enhancer binding protein (Ntambi and Kim, 2000). It has been reported that PPARγ 
agonists induce adipogenesis of a variety of preadipocytes and stem cell lines into mature 
adipocytes (Chawla, et al., 1994). As a result, adiposity induced by anti-diabetic agents is a 
highly undesirable side effect since most patients with T2DM are overweight (Kumanyika, et al., 
2002).  
In order to evaluate whether the plant extracts acting as PPARγ agonists also induce 
adipogenesis, their effect on adipocyte differentiation was examined.  
Cell viability of 3T3-L1preadipocytes in response to treatment with each extract was 
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determined prior to the differentiation assay. Of the eleven plants acting as PPARα and PPARγ 
modulators, four (Bixa orellana, Columnea nicaraguensis, Homalomena wendlandii, and Talisia 
nervosa) were selected for evaluating their adipogenic effects on insulin-stimulated 3T3-L1 
adipocytes, based on their cytotoxicity to 3T3-L1preadipocytes. 
Rosiglitazone was selected as the positive control since it is one of the most specific 
thiazolidinediones, which are known to have marked adipogenic effects on preadipocyte in vitro 
(Kletzien, et al., 1992). As shown in Figure 4.3A, a significant induction of adipocyte 
differentiation by the treatment of rosiglitazone was observed by Oil red O staining. This result 
correlated with the increased lipid accumulation, indicated by Nile Red fluorescent reagent as 
seen in Figure 4.3B.  
A concentration-dependent increase in adipocyte differentiation was seen with Columnea 
nicaraguensis as determined by Oil red O staining (Figure 4.3A). This result is consistent with 
the increased lipid accumulation, determined by Nile Red fluorescent reagent as shown in Figure 
4.3B. At the highest concentration of 50 µg/mL, the percent lipid content of adipocytes was 
increased to 146.08 ± 1.40% (P < 0.001), compared to vehicle control (100%). 
In contrast, Bixa orellana, Homalomena wendlandii, and Talisia nervosa exhibited no 
significant increase in adipogenesis (Figure 4.3A and 4.3B) despite of their PPARγ agonistic 
action in HepG2 cells.   
In summary, the ethanolic extracts of eleven plants: Bixa orellana, Bursera simaruba, 
Chaptalia nutans, Columnea nicaraguensis, Elephantopus mollis, Ficus colubrinae, Garcinia 
madruno, Homalomena wendlandii, Tabernaemontana panamensis, Talisia nervosa, and 
Viburnum costaricanum, were found to be dual agonists for both PPARα and PPARγ. Among 
them, Bixa orellana, Columnea nicaraguensis, Homalomena wendlandii, and Talisia nervosa 
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were found to enhance cellular glucose uptake in HepGe2 cells. The extract of Columnea 
nicaraguensis was found to enhance adipogenesis. Therefore, Bixa orellana, Homalomena 
wendlandii, and Talisia nervosa as dual PPARα and PPARγ modulators, possess the properties 
of enhancing cellular glucose uptake without showing any adipogenesis. They may represent 
good candidates for the treatment of metabolic abnormalities.    
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B. orellana (50 g/mL)B. orellana (5 g/mL)
C. nicaraguensis (50 g/mL)C. nicaraguensis (5 g/mL)
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Figure 4.3 Effect of the extracts on adipocyte differentiation in 3T3-L1 cells. 3T3-L1 cells were exposed 
to 10% FBS/DMEM containing 10 µg/mL insulin and 1 μM dexamethasone in the presence or absence of 
samples at different concentrations (5, 25 and 50 μg/mL). After 8 days, treated cells were stained with Oil 
red O for morphological assessment by microscopy (A) and lipid content was determined using Nile Red 
fluorescent reagent (B). Representative result from duplicate experiments is presented and data are 
expressed as the means ± S.D.; *P < 0.05, **P < 0.01 and ***P < 0.001 compared with the vehicle 
control.                        
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4.4 NF-κB Inhibition 
4.1.1 General Experimental Procedures 
Human chondrosarcoma (SW1353) cells were obtained from ATCC and cultured in 
DMEM /F12 medium supplemented with 10% FBS, 100 units/mL penicillin and 100 μg/mL 
streptomycin at 37°C in an atmosphere of 5% CO2 and 95% humidity. This reporter gene assay 
for the identification of NF-κB inhibitors was carried out as described previously with some 
modification (Subbaramaiah, et al., 2001). SW1353 cells (1.2 x 10
7
) were washed once in an 
antibiotic and FBS-free DMEM/F12 medium, and then resuspended in 500 µL of antibiotic-free 
medium containing 2.5% FBS. The pBIIXLUC luciferase plasmid construct (gift from Dr. 
Riccardo Dalla-Favera, Department of Pathology, Columbia University) was added to the cell 
suspension at a concentration of 25 µg/mL and incubated for 5 min at room temperature. The 
cells were electroporated at 160 V for single 70 msec pulse using BTX disposable cuvette with a 
Square electroporator T820. Following electroporation, 1.25 x 10
5
 cells per well were plated in 
200 µL of DMEM/F12 medium containing 10% FBS and antibiotics. After 24 h, the cells were 
exposed to different concentrations of plant extracts (1, 10, 100 µg/mL) or positive control 
parthenolide (0.125, 1.25, 12.5 M) for 30 min and then induced with 70 ng/mL of phorbol 12-
myristate 13-acetate (PMA) (Sigma-Aldrich, St Louis, MO) for 8 h for the activation of NF-κB. 
Cells were lyzed by adding 40 µL of a 1:1 mixture of luciferase assay system and PBS 
containing 1 mM calcium and magnesium. In order to detect nonspecific inhibition of luciferase 
expression due to cytotoxicity, inhibition of luciferase enzyme activity or light output, the 
transcription factor specificity protein 1 (Sp1) reporter plasmid (pGL3-promoter), obtained from 
Promega (Madison, WI), was used as an internal control because it is unresponsive to 
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inflammatory mediators such as PMA.  Light output was detected on a SpectraMax M5 plate 
reader. Percent inhibition of NF-κB was calculated as compared to vehicle control (DMSO). IC50 
values were estimated from concentration response curves.  
4.4.2 Results and Discussion 
In order to investigate the anti-inflammatory potential of the plants involved in this study, 
a total of 83 ethanolic plant extracts from 75 species were assessed for NF-κB inhibition in a 
concentration range of 1-100 µg/mL.  
Out of eighty-three, seventeen plant extracts (20.5%) inhibited NF-κB transcriptional 
activity in PMA-treated chondrosarcoma cells with IC50 values in the range of 28-52 µg/mL, as 
shown in Table 4.4.  
The most active plant extracts were Clusia rosea, Lisianthius peduncularis, Piper 
friedrichsthalii, Renealmia cernua, Lasianthaea fruticosa, Trichilia pallida, and Clavija 
costaricana, which caused a 50% inhibition of NF-κB at 28.0, 31.0, 31.5, 34.5, 35.0, 39.5, and 
40.0 µg/mL, respectively (Table 4.4). 
Under the same biological test condition, parthenolide, a positive control, inhibited NF-
κB transcriptional activation with an IC50 of 0.55 µM.  
On the other hand, none of the plant extracts showed inhibition of SP-1 indicating that 
their effect on N F-κB was specific. SP-1 was used as a control because it is unresponsive to 
inflammatory mediators such as PMA and its measurement is useful for detecting agents that non 
specifically inhibit luciferase expression because of cytotoxicity, inhibition of luciferase enzyme 
activity or light output.  
 
 59 
This is the first report of the inhibition of NF-κB mediated transcription in PMA-treated 
cells by the plants: Clusia rosea, Lisianthius peduncularis, Piper friedrichsthalii, Renealmia 
cernua, Lasianthaea fruticosa, Trichilia pallida, and Clavija costaricana. Therefore, they may 
have potential as anti-inflammatory agents due to the fact that NF-κB is highly activated at the 
sites of inflammation in diverse diseases.     
Table 4.4 Inhibition of NF-κB in SW1353 cells by Panamanian plant extracts. 
Family / Plant Species Part SP-1
% Inhibition (100 µg/mL)  IC50 (µg/mL)  IC50 (µg/mL)
Asteraceae 
Elephantopus mollis  Kunth Aerial parts 88.30 ± 11.0 45.0 ± 7.07 >100
Lasianthaea fruticosa  (L.) K.M. Becker Leaves 76.07 ± 8.35 35.0 ± 9.90 NA
Begoniaceae
Begonia urophylla  Hook. Whole plant 74.18 ± 5.90 48.0 ± 15.56 >100
Burseraceae
Bursera simaruba  (L.) Sarg. Bark 69.45 ± 5.10 50.5 ± 0.71 NA
Calophyllaceae
Calophyllum longifolium  Willd. Branch 73.35 ± 0.98 43.0 ± 8.49 ≈100
Clusiaceae
Clusia rosea  Jacq. Fruit 93.84 ± 1.56 28.0 ± 4.24 >100
Dichapetalaceae
Dichapetalum axillare  Woodson Stem 61.95 ± 2.32 65.0 ± 7.07 NA
Gentianaceae
Lisianthius peduncularis  L.O. Williams Leaves 87.58 ± 5.43 31.0 ± 1.41 >100
Malvaceae
Trichospermum galeottii  (Turcz.) Kosterm. Leaves 77.20  ± 10.99 48.5 ± 2.12 >100
Melastomataceae 
Ossaea quinquenervia  (Mill.) Cogn. Leaves 90.06 ± 11.21 35.5 ± 0.71 ≈100
Meliaceae
Trichilia pallida  Sw. Leaves 83.60 ± 3.36 39.5 ± 2.12 >100
Piperaceae 
Piper friedrichsthalii  C. DC. Leaves 87.10 ± 7.55 31.5 ± 4.95 NA
Piper hispidum  Sw. Leaves 71.21 ± 5.90 50.5 ± 0.71 NA
Primulaceae
Clavija costaricana  Pittier Leaves 92.27 ± 6.80 40.0 ± 2.83 ≈100
Rubiaceae
Chiococca alba  (L.) Hitchc. Leaves 78.11 ± 1.61 44.5 ± 4.95 NA
Solanaceae
Cestrum latifolium  Lam. Leaves 77.99 ± 6.97 52.0 ± 4.24 >100
Zingiberaceae
Renealmia cernua  (Sw. ex Roem. & Schult.) 
J.F. Macbr.
Root 79.30 ± 7.15 34.5 ± 9.19 NA
Parthenolide 0.55 ± 0.14 6.0  ± 1.0
NF-κB
 
NA: No Activity 
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4.5 iNOS Inhibition 
4.5.1 General Experimental Procedures 
Mouse macrophage (RAW 264.7) cells were obtained from ATCC and cultured in phenol 
red free RPMI medium (Hyclone, South Logan, UT) containing 10% BCS, 60 μg/mL amikacin 
(Sigma-Aldrich, St Louis, MO) at 37°C in a humidified 5% CO2 incubator. The assay for the 
identification of iNOS inhibitors was carried out as described previously with some modification 
(Quang, et al., 2006). RAW 264.7 cells were seeded at a density of 1  105 cells/well in 96-well 
tissue culture plates and incubated for 24 h. After incubation, the cells were treated with plant 
extracts (1, 10, 100 µg/mL) or positive control parthenolide (0.125, 1.25, 12.5 M) for 30 min 
(Fiebich, et al., 2002). Lipopolysaccharide (LPS, 5 µg/mL) (Sigma-Aldrich, St Louis, MO) was 
added to induce the cells and the plates were incubated for 24 h. An aliquot of the supernatant 
(35 μL) was transferred from each well to a new plate and 35 μL of Griess reagent (Sigma-
Aldrich, St Louis, MO) were added and incubated for 15 min. The absorbance was read at dual 
wavelength 540/630 nm using EL 312e plate reader. The percent inhibition of nitrite production 
by extracts was calculated as compared to vehicle control (DMSO). IC50 values were calculated 
from concentration response curves. 
4.5.1.1 Cytotoxicity to RAW 264.7 Cells 
The effect of plant extracts on the viability of RAW 264.7 cells was also evaluated by the 
Neutral Red (Sigma-Aldrich, St Louis, MO) colorimetric method (Borenfreund, et al., 1990). 
The cells were seeded in 96-well tissue culture-treated plates at a density of 25,000 cells/well. 
After 24 h, plant extracts were added at different concentrations and cells were further incubated 
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for 48 h. The medium was discarded and 100 L of neutral red solution (1 mg/mL) was added to 
each well and plates were incubated at 37°C under 5% of CO2 for 90 min. Cells were 
subsequently washed with warm saline and the dye was dissolved by adding 100 L of 0.33% 
hydrochloric acid in isopropanol. The absorbance was measured at dual wavelength 490/630 nm 
using EL 312e plate reader. Cell viability was calculated in comparison to vehicle control.  
4.5.2 Results and Discussion 
Since excessive generation of NO contributes significantly to the progress of 
inflammation and subsequent development of MetS, it was desirable to evaluate whether the 
plant extracts involved in this study inhibit the NO generation. All the 83 ethanolic plant extracts 
were examined for iNOS inhibition which was measured in terms of decrease in intracellular 
production of NO.  
Out of eighty-three plant extracts tested in a concentration range of 1-100 µg/mL, twenty-
seven (32.5%) showed inhibition of iNOS and therefore affect the cellular NO levels in LPS-
stimulated macrophages. These 27 plants reduced the nitrite accumulation by over 50% at a 
concentration of 100 µg/mL, as seen in Table 4.5.  
Twenty of these plant extracts decreased the NO production with IC50 values in the range 
of 22.5-49.5 and seven plant extracts with IC50 values in the range of 51.5-86.0 µg/mL. 
The most active plants were: Simaba cedron, Callichlamys latifolia, Piper 
friedrichsthalii, Ochroma pyramidale, Costus pulverulentus, Begonia urophylla, and Coussarea 
curvigemmia, which caused a 50% inhibition of iNOS at 22.5, 24.5, 32.0, 35.5, 37.0, 38.0, and 
38.5 µg/mL, respectively.  
 
 62 
Parthenolide was used as a positive control and caused a decrease in NO production with 
an IC50 value of 0.67 µM. Previous studies have found parthenolide to be an inhibitor of 
iNOS/NO synthesis (Fiebich, et al., 2002). 
In addition, most of the plant extracts did not affect the viability of RAW 264.7 cells 
during the 48 h incubation period and were not considered cytotoxic. Only the extracts of Clavija 
costaricana and Trichospermum galeottii showed a decrease in cell viability to 29.1 and 38.7 at a 
concentration of 100 µg/mL, respectively.    
In summary, the extracts of thirteen plants: Elephantopus mollis, Lasianthaea fruticosa, 
Begonia urophylla, Bursera simaruba, Calophyllum longifolium, Clusia rosea, Dichapetalum 
axillare, Trichospermum galeotti, Ossaea quinquenervia, Piper friedrichsthalii, Clavija 
costaricana, Chiococca alba, and Renealmia cernua exhibited inhibition of NF-κB and iNOS 
activity. As a result, these plants may regulate the process of inflammation through mediating 
multiple targets that are involved in several inflammatory pathways. They may represent 
potential sources to develop new agents with beneficial anti-inflammatory properties.  
In addition, this is the first report of these plants as inhibitors of NF-κB and iNOS. 
Nevertheless, Bursera simaruba has been used as anti-inflammatory in the ethnomedicinal 
practice and has exhibited anti-inflammatory activity on the adjuvant-carrageenan-induced 
inflammation in rats (Carretero, et al., 2008; Noguera, et al., 2004). 
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Table 4.5 Inhibition of iNOS in RAW 264.7 cells by Panamanian plant extracts. 
Family / Plant Species Part Cell viability (%)
% Inhibition (100 µg/mL)  IC50 (µg/mL) (100 µg/mL)
Apocynaceae 
Odontadenia puncticulosa  (Rich.) Pulle Stem 52.78 ± 3.40 86.0 ± 16.97 67.2
Peltastes colombianus  Woodson Leaves 64.42 ± 3.97 59.5 ± 6.36 97.3
Asteraceae 
    Elephantopus mollis  Kunth Aerial parts 85.78 ± 1.80 39.0 ± 1.41 46.6
Lasianthaea fruticosa  (L.) K.M. Becker Leaves 81.65 ± 6.23 39.5 ± 4.95 76.9
Begoniaceae
    Begonia urophylla  Hook. Whole plant 88.64 ± 10.58 38.0 ± 8.49 102.4
Bignoniaceae
Callichlamys latifolia  (Rich.) K. Schum. Leaves 97.89 ± 2.47 24.5 ± 6.36 70.0
Burseraceae
Bursera simaruba  (L.) Sarg. Bark 71.47 ± 12.31 44.5 ± 9.19 49.2
Calophyllaceae
Calophyllum longifolium  Willd. Branch 90.60 ± 7.81 42.5 ± 10.61 87.8
Calophyllum longifolium  Willd. Leaves 74.29 ± 7.35 51.5 ± 2.12 103.7
Clusiaceae
Clusia rosea  Jacq. Fruit 75.19 ± 4.38 47.5 ± 3.54 105.7
Costaceae
Costus pulverulentus  C. Presl Leaves 80.36 ± 5.20 37.0 ± 5.66 72.7
Cucurbitaceae
 Psiguria warscewiczii  (Hook. f.) Wunderlin Aerial parts 69.01 ± 8.09 54.5 ± 7.78 79.0
Dichapetalaceae
Dichapetalum axillare  Woodson Stem 89.44 ± 6.17 45.0 ± 7.07 101.0
Malvaceae 
Ochroma pyramidale  (Cav. ex Lam.) Urb. Leaves 81.36 ± 14.14 35.5 ± 7.78 84.6
Quararibea pterocalyx  Hemsl. Leaves 83.29 ± 8.73 41.0 ± 4.24 86.3
Trichospermum galeottii  (Turcz.) Kosterm. Leaves 74.42 ± 7.67 49.5 ± 7.78 38.7
Melastomataceae
Miconia affinis  DC. Leaves 69.63 ± 1.13 49.0 ± 1.41 68.5
Ossaea quinquenervia  (Mill.) Cogn. Leaves 58.14 ± 4.38 77.5 ± 10.61 98.0
Meliaceae
Trichilia havanensis  Jacq. Leaves 58.18 ± 5.78 70.0 ± 14.14 79.7
Piperaceae 
Piper friedrichsthalii  C. DC. Leaves 93.24 ± 2.04 32.0 ± 5.66 80.7
Piper hispidum  Sw. Leaves 74.37 ± 6.16 46.0 ± 5.66 86.8
Primulaceae
Clavija costaricana  Pittier Leaves 93.80 ± 2.19 42.5 ± 2.12 29.1
Rubiaceae
Chiococca alba  (L.) Hitchc. Leaves 65.22 ± 2.84 51.5 ± 3.54 58.5
Coussarea curvigemmia  Dwyer Leaves 76.88 ± 3.03 38.5 ± 2.12 82.7
Psychotria orosiana  Standl. Leaves 69.33 ± 1.03 43.0 ± 2.83 57.3
Simaroubaceae
Simaba cedron  Planch. Leaves 88.25 ± 6.98 22.5 ± 10.61 84.3
Zingiberaceae
Renealmia cernua  (Sw. ex Roem. & Schult.) 
J.F. Macbr.
Root 87.60 ± 6.58 43.5 ± 4.95 89.0
Parthenolide 0.67 ± 0.29
 iNOS
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4.6 LXRα Activation  
4.6.1 General Experimental Procedures 
HepG2 cells were cultured in DMEM/F12 medium supplemented with 10% FBS, 100 
units/mL penicillin and 100 g/mL streptomycin in a humidified atmosphere of 5% CO2 at 37°C. 
Cells were transfected with LXRα (pCMX-hLXRα) together with LXR response element-driven 
luciferase reporter (LXRE-tk-luc) provided by Dr. Laura Liscum (Tufts University School of 
Medicine, Boston) plasmid DNA (25 µg/500 µL cell suspension) by electroporation at 160 V for 
single 70 msec pulse using BTX disposable cuvettes with a Square electroporator T820. 
Transfected cells were plated in 96-well tissue culture plate at 5 x 10
4 
cells/well and incubated 
for 24 h. Different concentrations of plant extracts (25, 50, 100 µg/mL) or positive control 
(25(R) hydroxylcholesterol, 25 µM) (Sigma-Aldrich, St Louis, MO) were added. After 
incubation for 24 h, the cells were lysed by adding 40 L of a 1:1 mixture of luciferase assay 
system and PBS containing 1 mM calcium and magnesium. Light output was detected on a 
SpectraMax M5 plate reader. Plant extracts showing a 2-fold activation or more were considered 
active. 
4.6.2 Results and Discussion 
In a similar way as PPARs, LXR inhibits the production of inflammatory mediators in a 
manner reciprocal to its regulation of lipid metabolism. Thus, LXR has been considered as a 
significant target in treating metabolic diseases. For this reason, the plant extracts that showed 
specific PPARα, PPARγ or dual activation were evaluated for LXR transcriptional activity in 
HepG2 cells. 
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Twenty-seven ethanolic plant extracts were subjected to screening their agonist effect on 
LXR transcriptional activity in a concentration range of 25-100 µg/mL.  
Out of these, seven plants: Ficus colubrinae, Bursera simaruba, Tabernaemontana 
panamensis, Odontadenia puncticulosa, Garcinia madruno, Philodendron radiatum, and 
Xylosma chlorantha were highly effective with fold activations of 3.79, 3.29, 3.06, 2.90, 2.26, 
2.14, and 2.14, respectively for LXR at a concentration of 100 µg/mL as seen in Table 4.6. 
On the other hand, twelve plants: Homalomena wendlandii, Solenophora calycosa, 
Talisia nervosa, Elephantopus mollis, Coutarea hexandra, Columnea nicaraguensis, Coutarea 
hexandra, Bixa orellana, Pentagonia nuciformis, Chaptalia nutans, Mayna odorata, and 
Viburnum costaricanum showed an increase in LXR activity in the range of 1.53 to 1.99-fold, at 
100µg/mL (Table 4.6).  
In summary, these plants showed specific PPARα, PPARγ or dual activation, as well as 
LXR transcriptional activation and this is their first report of their LXR agonistic effect. 
Therefore, they represent a reservoir of new therapeutic agents directed toward the mitigation of 
metabolic abnormalities due to the close association of these nuclear receptors with T2DM, 
hypercholesterolemia, inflammation, and obesity.  
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Table 4.6 Activation of LXRα in HepG2 cells by Panamanian plant extracts. 
Family / Plant Species Part                   LXRα (Fold Activation)
100 μg/mL 50 μg/mL 25 μg/mL
Achariaceae 
Mayna odorata  Aubl. Leaves 1.94 ± 0.05 1.76 ± 0.16 1.53 ± 0.09
Adoxaceae 
Viburnum costaricanum  (Oerst.) Hemsl. Leaves 1.99 ± 0.03 1.50 ± 0.10 1.64 ± 0.10
Apocynaceae 
    Odontadenia puncticulosa (Rich.) Pulle Stem 2.90 ± 0.55 2.33 ± 0.65 1.50 ± 0.18
Tabernaemontana panamensis  (Markgr., 
Boiteau & L. Allorge) Leeuwenb. 
Leaves 3.06 ± 0.03 2.48 ± 0.20 2.20 ± 0.14
Araceae
Homalomena wendlandii  Schott Leaves 1.53 ± 0.46 1.59 ± 0.08 1.04 ± 0.31 
Philodendron radiatum  Schott Whole plant 2.14 ± 0.23 1.79 ± 0.34 1.80 ± 0.39
Asteraceae 
Chaptalia nutans  (L.) Pol. Root 1.89 ± 0.35 1.47 ± 0.14 1.62 ± 0.15
Elephantopus mollis  Kunth Aerial parts 1.66 ± 0.16 1.53 ± 0.20 1.37 ± 0.19
Bixaceae
Bixa orellana  L. Stem 1.85 ± 0.25 1.08 ± 0.07 1.34 ± 0.13
Burseraceae
Bursera simaruba  (L.) Sarg. Bark 3.29 ± 0.20 3.10 ± 0.25 1.46 ± 0.19
Trattinnickia aspera  (Standl.) Swart Leaves 0.98 ± 0.32 1.37 ± 0.25 1.01 ± 0.29
Calophyllaceae
Calophyllum longifolium  Willd. Leaves 0.95 ± 0.11 1.35 ± 0.51 1.66 ± 0.40
Clusiaceae
Garcinia madruno  (Kunth) Hammel Leaves 2.26 ± 0.08 2.22 ± 0.11 1.87 ± 0.05
Gesneriaceae
Chrysothemis friedrichsthaliana  (Hanst.) 
H.E. Moore
Root 1.35 ± 0.52 1.19 ± 0.14 0.98 ± 0.15
Columnea nicaraguensis  Oerst. Leaves 1.84 ± 0.33 1.68 ± 0.63 1.25 ± 0.16
Solenophora calycosa  Donn. Sm. Leaves 1.56 ± 0.20 1.57 ± 0.14 1.37 ± 0.41
Moraceae
Ficus colubrinae  Standl. Stem 3.79 ± 0.03 3.11 ± 0.11 1.89 ± 0.12
Piperaceae 
Piper friedrichsthalii  C. DC. Leaves 0.74 ± 0.12 1.33 ± 0.28 1.81 ± 0.15
Rubiaceae
Coutarea hexandra  (Jacq.) K. Schum. Flower 1.70 ± 0.04 0.98 ± 0.19 1.24 ± 0.07
Pentagonia nuciformis  Dwyer Leaves 1.44 ± 0.08 1.51 ± 0.11 1.14 ± 0.31
Pentagonia nuciformis  Dwyer Stem 1.86 ± 0.43 1.50 ± 0.28 1.73 ± 0.35
Warszewiczia coccinea  (Vahl) Klotzsch Leaves 1.95 ± 0.09 1.61 ± 0.12 1.28 ± 0.40
Salicaceae 
Xylosma chlorantha  Donn. Sm. Leaves 2.14 ± 0.11 1.97 ± 0.22 2.00 ± 0.21
Sapindaceae 
Siparuna guianensis  Aubl. Fruit 1.14 ± 0.15 0.93 ± 0.27 0.93 ± 0.11
Talisia nervosa  Radlk. Leaves 1.59 ± 0.33 1.38 ± 0.16 1.57 ± 0.28
Talisia nervosa  Radlk. Stem 1.36 ± 0.27 1.53 ± 0.27 1.53 ± 0.60
22(R)-hydroxycholesterol (25 μM) 3.04 ± 0.18  
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CHAPTER 5                                                                               
PHYTOCHEMICAL INVESTIGATION 
During the last quarter century, the biomedical potential of herbal drugs used by the 
Amerindian population has been investigated. Nevertheless, there is an urgent need to intensify 
the efforts to study the untapped Panamanian flora as its potential as a source of new therapeutic 
agents has not been fully explored.  
Therefore, a collection of Panamanian plant extracts was evaluated through a series of 
molecular targets (PPARα, PPARγ, NF-κB, LXR and iNOS) related to metabolic disorders. Due 
to a close association of metabolic syndrome, with oxidative stress and inflammatory processes, 
there has been an increased interest in these molecular targets and the drugs or phytochemicals 
affecting the multiple targets are emerging as important class of therapeutic agents. 
Plants were selected for bioassay-guided fractionation based on their promising activities 
against the targets related to the conditions of inflammation and MetS, phytochemical 
background, and traditional use.  
In order to start the phytochemical study, high-performance thin-layer chromatography 
(HPTLC) analysis was performed for selected plant extracts. 
 
 
 68 
Procedure 
Chromatographic equipment 
Linomat 5 semi-automatic applicator, TLC scanner 3, reprostar 3 along with win CATS 4 
software ver. 1.3.2 (CAMAG, Switzerland). Twin trough chamber 10 x 10 cm (Analtech, USA). 
HPTLC plates  
Glass plates (Merck, Germany) with silica gel 60F254 (10 × 10 cm). 
Development 
Chamber saturation was done using 10×10 cm whatman filter paper for 20 min. 
Development was in three different solvent systems: 
1. CHCl3 : MeOH (9:1) as shown in Figure 5.1 
2. Toluene : Ether (1:1 saturated with10% acetic acid) as seen in Figure 5.2 
3. Lower layer of CHCl3 : MeOH : H2O (65:35:10.5) as shown in Figure 5.3  
Evaluation 
The plates were dried and images were taken at 254 nm, 366 nm, and white light, before 
and after dipping in reagent (anisaldehyde).   
 
1.   Odontadenia puncticulosa   6.   Bursera simaruba  
2.   Bixa orellana     7.   Talisia nervosa (Leaves)  
3.   Chaptalia nutans     8.   Talisia nervosa (Stem) 
4.   Ficus colubrinae     9.   Calophyllum longifolium 
5.   Xylosma chlorantha    10. Coutarea hexandra 
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Figure 5.1 HPTLC in CHCl3 : MeOH (9:1). 
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 Figure 5.2 HPTLC in Toluene : Ether (1:1 saturated with10% acetic acid). 
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Figure 5.3 HPTLC in lower layer of CHCl3 : MeOH : H2O (65:35:10.5). 
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5.1 Talisia nervosa Radlk  
Talisia nervosa was selected for bioassay-guided fractionation based on the biological 
activities against the molecular targets involved in this study.  
Firstly, this plant showed PPARα and PPARγ dual modulation. In addition, Talisia 
nervosa increased the insulin-stimulated glucose uptake into HepG2 cells and it did not cause 
significant increase in adipogenesis despite of its PPARγ agonistic action. Secondly, Talisia 
nervosa did not show inhibition of NF-κB showing its specificity towards PPARs as the nuclear 
receptor targets. Finally, this plant also increased the LXR transcriptional activation. This data 
suggest that Talisia nervosa may play an important role in the constellation of metabolic 
abnormalities related to MetS. 
This Panamanian plant belongs to the Sapindaceae family and it is also called mamón de 
monte. Talisia nervosa is distributed in the tropical moist forest and tropical wet forest of the 
central and Caribbean part of Panama as shown in Figure 5.4.  
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Figure 5.4 Distribution of Talisia nervosa in Panama. The figure was reproduced with appropriate 
permission from the Smithsonian Tropical Research Institute. 
 
The pulp of this plant is consumed by Panamanian Choco natives (Duke, 1970). 
However, there is not much information available about its secondary metabolites and their 
biological activities. 
5.1.1 Description 
Polygamous shrubs or small trees, usually less than 5 m tall; trunk to 6 cm d.b.h., 
unbranched. Leaves pinnately compound, clustered near the apex, often 1 m or more long, 
lacking reduced leaflets at the apex; petioles ca. 25 cm long, terete; petiolules swollen, 5-10 mm 
long; leaflets usually 5-8 pairs, oblong-elliptic, acute at the apex and base, 20-45 cm long, 6.5-13 
cm wide, gla- brous above, glabrous to puberulent beneath. Thyrses small, arranged in a panicle 
to 70 cm long, widely branched, the major branches ribbed; branches, pedicels and calyces 
puberulent to tomentulose; pedicels short, to 2 mm long, articulate be- low the calyx. Flowers 
white; calyx bowl shaped, to ca. 2 mm long, 5-lobed to about the middle, the lobes indurate, 
acute, ciliate; petals 5, oblong, 3-5 mm long, acute to blunt at the apex, spreading above the 
calyx, glabrous, the scale exceeding the petal, sericeous, tufted and slightly spreading at the 
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apex; disc raised, 5-an- gulate, the points alternating with the petals; stamens 5 or 8, 3 often 
reduced or aborted, equalling the scales, to 5 mm long, the filaments weakly pubescent, shorter 
than the anther, the anthers oblong, 1-4 mm long, the connective beaked at the apex; ovary 
densely pubescent, those of the staminate flowers less than 2 mm long, the style lacking, the 3 
minute stigmas hidden by the pubescence of the ovary; bisexual flowers with the ovary narrowly 
ovoid, sericeous, the style about as long as the ovary, the stigma capitate, held at about the level 
of the anthers. Fruits ellipsoid to globose, brown, sharply apiculate at the apex, sparsely 
pubescent, minutely lenticellate, usually 2-3.5 cm long, with a 2-3 mm thick, woody pericarp; 
seeds ellipsoid, the side flat if more than one, 1.5-2.5 cm long, embedded in a firm or jellylike, 
whitish to orange mesocarp. The species flowers in the dry season, December to April, and fruits 
mature in mid to late rainy season, July to October (Tropicos). 
5.1.2 Plant Material 
Stems of Talisia nervosa (Figure 5.5) were collected from National Park Altos de 
Campana, Chame, Panama (N 08
o
 41’ 27.2’’ W 079o 58’ 02.2’’) by botanist Alex Espinosa. Its 
taxonomic identity was established by Prof. Mireya D. Correa, at the National Herbarium of the 
University of Panama, where the voucher specimen (Florpan No. 8735) is deposited. 
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Figure 5.5 Talisia nervosa in the tropical forest of Panama. Source: Alex Espinosa, CIFLORPAN, 
University of Panama. 
 
5.1.3 Extraction and Isolation                                      
The dried powdered stem of Talisia nervosa (1628 g) was extracted exhaustively with 
95% EtOH at room temperature for 24 h. The EtOH was removed by evaporation under reduced 
pressure to yield 86.5g of crude extract. The dry crude extract (86.5 g) was successively 
partitioned with hexane, CHCl3, EtOAc, BuOH and H2O. The bioassay-guided fractionation was 
monitored using the reporter gene assay for PPARα and PPARγ transcriptional activity (Figure 
5.6). The highest activation of both PPARα and PPARγ was observed in the EtOAc fraction (6.5 
and 7.5, respectively) at a concentration of 100 µg/mL. 
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Talisia nervosa 
Dry Stem 
(1628 g) 
HEXANE 
(4.79 g) 
 
PPAR = 2.4 
PPAR = 3.0 
 
CHCl3 
(2.81 g) 
 
PPAR = 2.2 
PPAR = 1.8 
 
EtOAc 
(18.38 g) 
 
PPAR = 6.5 
PPAR = 7.5 
 
BuOH 
(24.05 g) 
 
PPAR = 3.0 
PPAR = 4.5 
 
H2O 
(11.87 g) 
 
PPAR = 1.4 
PPAR = 1.7 
 
95%  EtOH  
Extract 
(86.5 g) 
PPAR = 2.3 
PPAR = 3.6 
 
 
 
 
Figure 5.6 Activity of each fraction is shown as fold activation of PPARα and PPARγ at a concentration 
of 100 µg/mL. 
 
The EtOAc fraction (10 g) was subjected to column chromatography using Polyamide 
(50-160 µm, 310 g) with gradient elution using MeOH-H2O (1:1 – 5:1) and MeOH-Acetone (3:1 
– 1:3). Fractions consisting of 20 mL each were collected and combined on the basis of their 
TLC profiles. Spots were detected by UV before and after spraying with vanillin-H2SO4. The 
bioassay-guided fractionation for PPARα and PPARγ was monitored (Figure 5.7). The combined 
fractions were further separated on Sephadex LH-20 with MeOH (100%), which leaded to the 
isolation of four known compounds: (-)-catechin (9.5 mg), methyl gallate (67.1 mg), ethyl gallate 
(11.0 mg), ß-D-glucopyranose, 1,4,6-tris (3,4,5-trihydroxybenzoate) (5.3 mg) (Figure 5.8). 
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T. nervosa 
Stem 
EtOAc 
10 g 
95-127 
193 mg 
PPAR=1.5 
PPAR=1.8 
128-170 
102 mg 
PPAR=2.5 
PPAR=3.2 
 
235-267 
83.5 mg 
PPAR=1.4 
PPAR=1.3 
 
 
268-324 
228 mg 
PPAR=0.8 
PPAR=1.2 
 
325-400 
285 mg 
PPAR=1.5 
PPAR=2.1 
 
451-564 
198 mg 
PPAR=2.8 
PPAR=5.7 
 
565-669 
138 mg 
PPAR=3.6 
PPAR=7.4 
761-869 
245 mg 
PPAR=4.9 
PPAR=5.9 
885-1331 
165 mg 
PPAR=.7 
PPAR=.7 
 
 
 
Figure 5.7 Activity of the EtOAc fractions are shown as fold activation of PPARα and PPARγ at a 
concentration of 100µg/mL. 
 
Structural elucidation for the isolated compounds was accomplished using NMR data. 
Comparisons with available spectrometry and spectroscopy data in the literature were also used 
for confirmation. Data from the 1D (
1
H and 
13
C) and 2D (COSY, HSQC and HMBC) NMR 
experiments were obtained using a Bruker AVANCE DRX400 NMR spectrometer (Bruker 
Biospin, Billerica, MA, USA) equipped with a 3-mm BBO probe (SN# 9606-3133) operating at 
a proton NMR frequency of 400.13 MHz at a temperature of 298 K with Bruker Topspin 
software (v.1.3).  
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(-)-catechin methyl gallate
9.5 mg 67.1 mg
ethyl gallate
11.0 mg 
β-D-glucopyranose, 1,4,6-tris (3,4,5-trihydroxybenzoate) 
5.3 mg 
 
Figure 5.8 Compounds isolated from Talisia nervosa. 
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Figure 5.9 
1
H NMR spectrum of (-)-catechin. 
 
 
 
Figure 5.10 
13
C NMR spectrum of (-)-catechin. 
 80 
 
Figure 5.11 
1
H NMR spectrum of methyl gallate. 
 
 
 
Figure 5.12 
13
C NMR spectrum of methyl gallate. 
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Figure 5.13 
1
H NMR spectrum of ethyl gallate. 
                  
Figure 5.14 
13
C NMR spectrum of ethyl gallate. 
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Figure 5.15 
1
H NMR spectrum of β-D-glucopyranose, 1,4,6-tris (3,4,5-trihydroxybenzoate). 
 
Figure 5.16 
13C NMR spectrum of β-D-glucopyranose, 1,4,6-tris (3,4,5-trihydroxybenzoate). 
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Figure 5.17 2D COSY experiment of β-D-glucopyranose, 1,4,6-tris (3,4,5-trihydroxybenzoate). 
 
        
Figure 5.18 2D HSQC experiment of β-D-glucopyranose, 1,4,6-tris (3,4,5-trihydroxybenzoate). 
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The BuOH fraction of Talisia nervosa showed good activity towards PPAR and PPAR 
(3.0 and 4.5-fold activation, respectively) at 100µg/mL. As a result, this fraction (20 g) was 
subjected to column chromatography using Polyamide 6 (50-160 µm, 310 g) with MeOH 
(100%). Fractions consisting of 1 L each were collected (Figure 5.19) 
 
 
T. nervosa 
Stem 
BuOH 
20 g 
 
1 
118 mg 
 
2 
7.3 g 
 
 
3 
1.08 g 
 
 
 
4 
274 mg 
 
 
5 
185 mg 
 
 
6 
156 mg 
 
 
7 
139 mg 
 
 
8 
107 mg 
 
 
9 
126 mg 
 
 
 
10 
128 mg 
 
 
11 
147 mg 
 
 
12 
138 mg 
 
 
13 
113 mg 
 
 
14 
87 mg 
 
 
Figure 5.19 Schematic representation of the fractionation of the BuOH fraction of Talisia nervosa. 
 
The fraction 2 showed good activity on PPAR with a 3.0 fold activation at a 
concentration of 100 µg/mL.  
As a result, 6.9 g of this fraction was subjected to column chromatography using Silica 
gel 60 (32-63 µm, 200 g) with gradient elution using EtOAc-CHCl3-MeOH-H2O (5:3:2:0.5 – 
5:3:5:0.5). Fractions consisting of 20 mL each were collected and combined on the basis of their 
TLC profiles. The compounds obtained from this column were sugars and the activity was weak. 
Therefore, they were not subjected to further investigation. 
The hexane fraction of Talisia nervosa (4.72 g) was subjected to column chromatography 
using Silica gel 60 (32-63 µm, 200 g) with gradient elution using CHCl3- EtOAc (98:2 – 80:20). 
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Fractions consisting of 20 mL each were collected and combined on the basis of their TLC 
profiles.  
Some of the fractions (YV-5-66-3, YV-5-66-5) from the previous column were a mixture 
of fatty acids according with the GC-MS data.  
The fraction YV-5-66-14 (252 mg) was subjected to Biotage chromatography using 
FLASH 40+M cartridge with gradient elution using Hexane- Acetone (95:5 – 60:40). Fractions 
consisting of 18 mL each were collected and combined on the basis of their TLC profiles. The 
fraction YV-5-78-5 was obtained from this column. Also from the same column the fraction YV-
5-78-9 was obtained and it had a mixture of two compounds that were difficult to separate.  
The fraction YV-5-66-12 (125 mg) was subjected to Biotage chromatography using 
FLASH 40+M cartridge with gradient elution using Hexane-Acetone (98:2 – 80:20) but the 
purification was not good. Therefore, a Sephadex column LH-20 (80.3 g) was performed with 
MeOH-CHCl3 (2:1). The fraction YV-5-86-7 obtained from this column was not pure and it 
showed a long chain of carbons with OH at the end according with the GC-MS data. 
The fraction YV-5-66-13 (910 mg) was subjected to Biotage chromatography using 
SNAP 100g cartridge with gradient elution using Hexane-Acetone (98:2 – 80:20). The fractions 
YV-5-92-8 and YV-5-92-9 from this column were combined (132 mg) and subjected to Biotage 
chromatography using SNAP 100g cartridge with CHCl3-EtOH (98:2). The fraction YV-5-96-5 
was obtained from this column. The fraction YV-5-92-4 (153 mg) was subjected to Biotage 
chromatography using SNAP 100g cartridge with CHCl3-EtOH (98:2). The fraction YV-6-1-3 
was obtained from this column and it showed a mixture of campesterol, stigmasterol, γ sitosterol 
according with the GC-MS data and they were not further studied.  
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5.1.4 Biological Activity of Compounds 
The four known compounds isolated from the EtOAc fraction of Talisia nervosa [(-)-
catechin (1), methyl gallate (2), ethyl gallate (3), and β-D-glucopyranose, 1,4,6-tris (3,4,5-
trihydroxybenzoate) (4)] were subjected to screening their agonistic effects on PPARα and 
PPARγ transcriptional activity in a concentration range of 25-100 µg/mL. 
As shown in Figure 5.19 and 5.20, compound 2 showed the strongest activity on PPARα 
and PPARγ with 3.0 and 13.0-fold activation, respectively, at a concentration of 100 µg/mL. 
This compound was previously isolated from Talisia nervosa by Dr. Gupta’s group and showed 
week in vitro antiplasmodial and antileishmanial activity (Calderon, et al., 2006). However, this 
appears to be the first report of compound 2 as dual modulator of PPARα and PPARγ. The 
PPARα and PPARγ activation was followed by compound 4 and compound 3 with 2.3, 8.6 and 
1.7, 4.6-fold activation, respectively, at a concentration of 100 µg/mL. Compound 3 was also 
isolated from Talisia nervosa by Dr. Gupta’s group and showed week in vitro antiplasmodial and 
antileishmanial activity. The dual activation of PPARα and PPARγ exhibited by compound 4 (a 
gallotannin) can be compared with the activity of another gallotannin 2,3,6-tri-O-galloyl-β-D-
glucose reported earlier (Min Hye Yang, et al., 2013). Compound 1 was less potent in PPARα 
than in PPARγ activation with 1.2 and 2.0-fold activation and was less potent compared with the 
compounds 2, 3, 4 (Figure 5.20 and 5.21). This observation is consistent with a previous report 
that showed very week activation of PPARα by catechin (Rimando, et al., 2016). In addition, 
earlier studies have shown that catechin possesses a potential agonistic effect on PPARγ (Shin, et 
al., 2009). Our results are consistent with these reports and support the hypoglycemic effect of 
catechin mediated by PPARγ activation. (Pitchai and Manikkam, 2012). 
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Figure 5.20 PPARα activation by isolated compounds (1-4). 
 
 
 
 
 
 
 
 
 
 
Figure 5.21 PPARγ activation by isolated compounds (1-4). 
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In order to evaluate whether the compounds acting as PPARγ agonists also induce 
adipogenesis, their effect on adipocyte differentiation was examined on isulin-stimulated 3T3-L1 
adipocytes. 
A concentration-dependent increase in adipocyte differentiation was seen with compound 
2 and 3 as determined by Oil red O staining (Figure 5.22). This result is consistent with the 
increase in lipid accumulation, determined by Nile Red fluorescent reagent as shown in Figure 
5.23. At the highest concentration of 50 µg/mL, the lipid content of adipocytes was increased to 
58% and 68% by compound 2 and 3, respectively, compared to vehicle control. However, in a 
recent study an inhibition of lipid accumulation in the early stages of adipogenesis by methyl 
gallate was reported (Naimur Rahman, et al., 2016). In our study we did not look at the inhibition 
of lipid accumulation.  
In contrast, compound 4 did not exhibit a significant increase in adipogenesis (Figure 
5.22 and 5.23) despite of its PPARγ agonistic action. This is similar to the effect of another 
gallotannin 2,3,6-tri-O-galloyl-β-D-glucose which did not enhance the adipocyte differentiation 
in 3T3-L1 cells (Min Hye Yang, et al., 2013). This data suggest that compound 4 may represent 
a good candidate for the treatment of MetS without the undesirable side effect of weight gain.   
              4 (50 g/mL)4 (12.5 g/mL)
2 (50 g/mL)2 (12.5 g/mL)Control Rosiglitazone (3 M)
3 (50 g/mL)3 (12.5 g/mL)  
Figure 5.22 Effect of the compounds (2-4) on adipocyte differentiation by Oil red O staining. 
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Figure 5.23 Effect of the compounds (2-4) on adipocyte differentiation in 3T3-L1 cells. 
 
Secondly, these compounds were assessed for NF-κB and iNOS in order to investigate 
their anti-inflammatory potential. As a result compound 1 did not show inhibition of PMA 
induced NF-κB activation which is in agreement with the previous report related to the effect of 
catechin on NF-κB (Wei Li, et al., 2013). In addition, no inhibition of iNOS activity in LPS 
induced macrophages was seen but a week effect of catechin on iNOS was reported earlier 
(Choi, et al., 2006). However, catechin has been shown to exhibit anti-inflammatory effects in 
microglial cells by suppressing the production of proinflammatory mediators and mitigating NF- 
κB activity (Syed Hussein, et al., 2015). 
Furthermore, compounds 2 and 3 caused a 50% inhibition of iNOS at 7.0 and 7.5 μg/mL, 
respectively, which is consistent with the previous studies which reported that methyl gallate and 
ethyl gallate inhibited LPS induced NO production and iNOS expression stimulated by LPS   
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(Chae, et al., 2010; Park, et al., 2011). On the other hand, these two compounds did not show any 
inhibition of NF-κB in PMA-treated cells as shown in Table 5.1. 
The effect of these compounds on the activity of LXR was also evaluated. Compound 4 
was the most effective with a fold activation of 5.32 for LXR at a concentration of 100 µg/mL as 
seen in Table 5.2. At a concentration of 100 µg/mL, compounds 1, 2, and 3 showed 1.74, 3.16, 
and 2.62-fold increase in LXR activity, respectively. The results of molecular docking showed in 
an earlier study suggests catechin as a potential inhibitor of atherogenesis through activating 
LXR signaling (Susanti, et al., 2015).  
In summary, these compounds may have potential in treating metabolic disorders due to 
their effect on the carbohydrate and lipid metabolism as well as they may influence the 
inflammatory process.   
 
Table 5.1 Anti-inflammatory activity of compounds 1-4. 
                    
Inhibition of NF-κB Inhibition of iNOS
Compound IC50 (μg/mL) IC50 (μg/mL)
1 NA NA
2 NA 7
3 NA 7.5
4 NA >50
Parthenolide (μM) 1.2 0.35  
 
 
 
Table 5.2 Activation of LXR by compounds 1-4. 
               
                  LXRα (Fold Activation)
Compound 100 μg/mL 50 μg/mL 25 μg/mL
1 1.74 2.15 1.71
2 3.16 1.99 1.99
3 2.62 1.53 1.45
4 5.32 2.12 1.49
25-hydroxycholesterol (25 μM) 4.67  
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5.2 Odontadenia puncticulosa (Rich.) Pulle 
Odontadenia puncticulosa was selected for bioassay-guided fractionation based on the 
biological activities against the molecular targets related to inflammation and metabolic 
disorders.  
This plant showed specificity towards PPARα transcriptional activation. Furthermore, it 
was highly effective on LXR activation indicating that it can play a role in lipid metabolism. On 
the other hand, the increase in transcriptional activity of NF-κB was not suppressed by 
Odontadenia puncticulosa. Nevertheless, this plant exhibited inhibition of iNOS and therefore it 
reduce the intracellular NO production which contributes significantly to the progress of 
inflammation. The phytochemical characterization of this plant species has not been reported in 
the literature. Thus, the isolation of bioactive compounds from this plant may lead to the 
mitigation of the array of metabolic disturbances.   
This Panamanian plant belongs to the Apocynaceae family and it is also called amali and 
latawira by the Panamanian native populations. Odontadenia puncticulosa is distributed in the 
tropical moist forest, tropical wet forest and premontane wet forest of Panama. The whole plant 
infusion is drunk for rubella by the Guaymi Indians in Panama (Joly, et al., 1990). However, 
there is not much information available about its secondary metabolites and their biological 
activities. 
5.2.1 Description 
Liana; sap milky, copious; stems glabrous, hollow and lenticellate in age, with a 
prominent interpetiolar ridge. Leaves opposite, glabrous; stipules 2, broadly ovate, softly 
puberulent, 2-3 mm long; petioles 1-2 cm long, stout; blades ± elliptic to ovate, shortly and 
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bluntly acuminate, obtuse to subcordate at base on larger leaves, 12-24 cm long, 6-12.5 cm wide, 
bicolorous, the midrib above pale green, impressed, lacking a central rib; reticulate veins 
prominulous and very closely spaced below. Thyrses axillary or terminal; axes of inflorescences, 
pedicels, and calyces densely puberulent; pedicels to 3 cm long; flowers 5-parted; calyx lobes 
narrowly ovate, 4-9 mm long, each with several squamellae inside; corolla tubular, 5-6.5 cm 
long, the tube pale green, minutely puberulent, constricted ca 1 cm above base, the lobes white, 
spreading at anthesis, ca 1 cm long but with one side extended laterally   2-2.5 cm; stamens 
included, attached at base of corolla throat, ca 2 cm long; filaments and anthers pubescent; 
anthers 5-6 mm long, connate, glued to the fusiform stigma; stigma 1; nectaries growing 
together, covering ovary. Follicles paired, widely divergent, cylindrical, 11-16 cm long, 1.5-2 cm 
diam, densely pubescent with short erect trichomes; pericarp with a thin leathery outer layer and 
a thicker woody layer; seeds many, the seminiferous portion cylindrical to angulate or flattened, 
13-20 mm long, obscurely striate, brown, narrowed only a few millimeters at apex; plume at 
apex light brown, to 6 cm long (Tropicos). 
5.2.2 Plant Material 
Stems of Odontadenia puncticulosa (Figure 5.24) were collected from National Park 
Chagres, Cerro Jefe, Panama (N 09
o
 13’ 33.9’’ W 079o  22’ 36.7’’) by botanist Alex Espinosa. Its 
taxonomic identity was established by Prof. Mireya D. Correa, at the National Herbarium of the 
University of Panama, where the voucher specimen (Florpan No. 8727) is deposited. 
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Figure 5.24 Odontadenia puncticulosa in the tropical forest of Panama. Source: Libardo Martinez, 
CIFLORPAN, University of Panama. 
 
5.2.3 Extraction and Isolation 
The ground dried stem of Odontadenia puncticulosa (2000 g) was extracted exhaustively 
by maceration with MeOH at room temperature for 24 h. The MeOH was removed by 
evaporation under reduced pressure (< 40°C) until dryness.  
The dry crude extract (162 g) was subjected to column chromatography using Silica gel 
(32-63 µm, 1000 g) with gradient elution using CHCl3 100%, CHCl3-MeOH (9:1 – 1:9) and 
MeOH 100%. Fractions consisting of 650 mL each were collected and combined on the basis of 
their TLC profiles. Spots were detected by UV 254/ 365 nm before and after spraying with 
vanillin-H2SO4. 
Fractions were evaluated through the reporter gene assay for PPARα and PPARγ 
transcriptional activity and the activity of each fraction is shown in Figure 5.25. 
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           O.puncticulosa 
Stem 
MeOH 
162 g 
         1 
2.49 g 
PPAR=1.0 
PPAR=0.8 
 
       2 
26.23 g 
PPAR=0.5 
PPAR=0.3 
 
        3 
1.30 g 
PPAR=1.3 
PPAR=0.7 
 
 
         4 
2.22 g 
PPAR=1.6 
PPAR=1.7 
 
 
       5    
0.98 g 
PPAR=1.7 
PPAR=1.5 
 
        6    
1.97 g 
PPAR=1.2 
PPAR=1.5 
 
       7    
2.22 g 
PPAR=2.2 
PPAR=2.4 
 
         8 
6.48 g 
PPAR=2.0 
PPAR=1.6 
 
 
        9    
16.64 g 
PPAR=2.5 
PPAR=0.5 
 
 
      10    
16.70 g 
PPAR=2.5 
PPAR=0.3 
 
      11   
22.52 g 
PPAR=1.9 
PPAR=0.7 
 
      12    
7.32 g 
PPAR=2.0 
PPAR=1.0 
 
      13 
3.97 g 
PPAR=1.5 
PPAR=0.8 
     14 
11.11 g 
    PPAR=1.5 
    PPAR=1.8 
 
Figure 5.25 Activity of the MeOH fractions are shown as fold activation PPARα and PPARγ at a 
concentration of 100µg/mL. 
 
The fractions 9 and 10 were combined (710.8 mg) and subjected to column 
chromatography using Sephadex LH-20 with MeOH (100%) and CHCl3 (100%). Fractions 
consisting of 18 mL each were collected and combined on the basis of their TLC profiles. Spots 
were detected by UV 254/ 365 nm before and after spraying with vanillin-H2SO4. 
Fractions were subjected to screening their agonist effect on PPARα and PPARγ 
transcriptional activity at a concentration range of 25-100 µg/mL. The activity is shown in Figure 
5.26. 
                       
 
9-10 
Fraction 
Sephadex LH-20 
710.8 mg 
3 
115.3 mg 
PPAR=1.2 
PPAR=1.0 
 
4 
33.9 mg 
PPAR=0.9 
PPAR=1.2 
 
 
5 
43.2 mg 
PPAR=1.6 
PPAR=1.9 
 
6 
77.9 mg 
PPAR=2.5 
PPAR=2.1 
 
7 
89.4 mg 
PPAR=1.6 
PPAR=2.3 
 
         8 
85.5 mg 
PPAR=1.6 
PPAR=1.2 
 
        9 
40.1 mg 
PPAR=2.0 
PPAR=1.4 
 
 
Figure 5.26 Activity of the MeOH fractions are shown as fold activation PPARα and PPARγ at a 
concentration of 100µg/mL. 
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A known compound Cinnammtanin B-1 was isolated from this plant (Figure 5.27). 
Structural elucidation for the isolated compound was accomplished using NMR and 
HRESITOFMS data. Comparisons with available spectrometry and spectroscopy data in the 
literature were also used for confirmation. Data from the 1D (
1
H and 
13
C) and 2D (COSY, 
HSQC, HMBC, and ROESY) NMR experiments were obtained using a Bruker AVANCE 
DRX400 NMR spectrometer (Bruker Biospin, Billerica, MA, USA) equipped with a 3-mm BBO 
probe (SN# 9606-3133) operating at a proton NMR frequency of 400.13 MHz at a temperature 
of 298 K with Bruker Topspin software (v.1.3). High-resolution mass spectra were obtained 
using an HRESITOFMS spectrometer with the Analyst QS software for data acquisition and 
processing (Agilent Series 1100 SL, ESI source model #G1969A, Agilent Technologies, Palo 
Alto, CA, USA). 
 
                             
 
 
Figure 5.27 Cinnamtannin B1 isolated from Odontadenia puncticulosa. 
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Figure 5.28 
1
H NMR spectrum of cinnamtannin B1. 
 
 
Figure 5.29 
13
C NMR spectrum of cinnamtannin B1. 
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Figure 5.30 2D COSY experiment of cinnamtannin B1. 
 
    
Figure 5.31 2D HSQC experiment of cinnamtannin B1. 
 98 
 
Figure 5.32 2D HMBC experiment of cinnamtannin B1. 
 
Figure 5.33 2D ROESY experiment of cinnamtannin B1. 
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Figure 5.34 ESI negative mode mass spectra of cinnamtannin B1. 
 
 
 
Figure 5.35 ESI positive mode mass spectra of cinnamtannin B1. 
 
5.2.4 Biological Activity of Cinnamtannin B1 
The known cinnamtannin B1 isolated from Odontadenia puncticulosa was subjected to 
screening its agonistic effect on PPARα and PPARγ transcriptional activity. 
This compound showed activity on PPARα and PPARγ with 2.2 and 3.1-fold activation, 
respectively, at a concentration of 25 µM. This is the first report of PPAR activation by this 
compound.   
Also, its effect on adipocyte differentiation was examined on isulin-stimulated 3T3-L1 
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adipocytes. A concentration-dependent increase in adipocyte differentiation was seen with 
cinnamtannin B1 as determined by Oil red O staining (Figure 5.36). This result is consistent with 
the increase in lipid accumulation, determined by Nile Red fluorescent reagent. At the highest 
concentration of 50 µg/mL, the lipid content of adipocytes was increased to 50% compared to 
vehicle control. Previous report showed that cinnamtannin B1 promoted cell proliferation of 
3T3-L1 adipocytes (Taher, et al., 2007). 
                     
Control Rosiglitazone (3 M)
Cinnamtannin B1 (50 g/mL)Cinnamtannin B1 (12.5 g/mL)  
Figure 5.36 Effect of cinnamtannin B1 on adipocyte differentiation by Oil red O staining. 
 
In addition, this compound did not show any inhibition of NF- κB and iNOS. Therefore, 
cinnamtannin B1 did not exhibit an anti-inflammatory action in terms of inhibition of these 
targets. 
Similarly, this compound was not effective in increasing the activity of LXR, the 
compound was also cytotoxic against HepG2 cells. This observation is in agreement with the 
strong antiproliferative effects of cinnamtannin B1against HepG2 cells as reported in an earlier 
study (Wen, et al., 2015). 
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CHAPTER 6                                                                                           
SUMMARY AND CONCLUSIONS 
Despite recent therapeutic advances, the prevalence of T2DM, insulin resistance and the 
metabolic syndrome has risen to epidemic proportions. The IDF estimated that nearly one-fourth 
of the world’s adult population has MetS. In addition, the Latin American populations exhibit a 
high prevalence of MetS, similar or even higher than developed countries. It is attributed to 
changes in their lifestyle, migration from rural to urban areas and a higher susceptibility to 
accumulate abdominal fat and develop more insulin resistance compared to other ethnically 
different populations. 
Current therapeutic agents are moderately effective in controlling the constellation of 
metabolic abnormalities. In addition, they have shown some unwanted side effects characterized 
by edema, gain weight and hepatotoxicity.   
 Taking this into account there is an urgent need to develop new therapeutic agents with 
broader efficacy, improve tolerability and fewer side effects.  
In order to accomplish this challenge, the present work attempted to identify promising 
ligands from natural products working through four molecular targets (PPARs, LXRs, NF-κB, 
and iNOS) due to their close association with the pathways involved in oxidative stress, 
inflammation and metabolic processes. 
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 Despite the considerable interest in these molecular targets, limited scientific studies 
exist regarding the mechanism of action of plants working through these specific pathways. 
As a consequence, this dissertation explored rationally the medical potential of the 
Panamanian plant biodiversity as a source of bioactive molecules to tackle the constellation of 
metabolic abnormalities through a collaborative international project, with the participation of 
the research centers from the United States and Panama (NCNPR – CIFLORPAN). 
A total of seventy-five plant species were studied following a biodiversity-based plant 
selection approach, endemism, and use by the Amerindians groups located in Panama. This 
collection of plants was subjected to 95% ethanol extraction and the resulting 83 ethanolic 
extracts were evaluated for their biological activity towards the selected targets. 
Firstly, these eighty-tree plant extracts were subjected to screening their agonist effect on 
PPARα and PPARγ transcriptional activity. The extracts of 22 plants were found to activate 
PPARα while 15 extracts activated PPARγ. A dual activation of PPARα and PPARγ was 
observed by 11plant extracts. Out of these, three plants (Bursera simaruba, Chaptalia nutans, 
and Talisia nervosa) were significantly more active than others. Most of the plant extracts did 
not affect the viability of HepG2 cells and were not considered cytotoxic. 
Secondly, in order to determine whether plant extracts activating both PPARα and 
PPARγ directly affect glucose uptake, their effect on 2-NBDG uptake was studied in HepG2 
cells. As result, the insulin-stimulated glucose uptake into HepG2 cells tended to be higher in 
cells treated with Talisia nervosa followed by Columnea nicaraguensis, and Homalomena 
wendlandii, indicating their promising potential in T2DM. 
Thirdly, the 11 plant extracts that showed dual activation of PPARα and PPARγ were 
evaluated in adipocyte differentiation assay in order to find out if they induced adipogenesis due 
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to their PPARγ agonistic effect. A concentration-dependent increase in adipocyte differentiation 
was seen with Columnea nicaraguensis indicating that this plant may have adipogenic effect. 
As a next stage, the plant extracts that showed specific PPARα, PPARγ or dual activation 
were evaluated for LXR transcriptional activity because this nuclear receptor inhibits the 
production of inflammatory mediators and regulates lipid metabolism. Seven plants were found 
to be highly effective on LXR transcriptional activation: Ficus colubrinae, Bursera simaruba, 
Tabernaemontana panamensis, Odontadenia puncticulosa, Garcinia madruno, Philodendron 
radiatum, and Xylosma chlorantha. 
Finally, the 83 plant extracts were assessed on NF-κB and iNOS inhibition assay to 
determine if they have anti-inflammatory properties. Piper friedrichsthalii was the most active 
plant that exhibited inhibitory effects on NF-κB and iNOS and it may have potential to follow 
studies as an anti-inflammatory agent.  
These active plants may represent a reservoir for new therapeutic agents directed towards 
the mitigation of metabolic abnormalities due to the close association of these molecular targets 
included in the study, with T2DM, hypercholesterolemia, inflammation, and obesity.  
Based on the previous results, use, and phytochemical background two plants, Talisia 
nervosa and Odontadenia puncticulosa were selected for bioassay-guided fractionation. 
The bioassay-guided fractionation of Talisia nervosa led to the isolation of four known 
compounds: (-)-catechin, methyl gallate , ethyl gallate, and  ß-D-glucopyranose, 1,4,6-tris (3,4,5-
trihydroxybenzoate). 
In a similar way, the bioassay-guided fractionation of Odontadenia puncticulosa led to 
the isolation of one known compound: cinnamtannin B1 with dual PPAR agonistic activity 
which was not reported earlier. 
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These isolated compounds may be considered as important ligands towards multiple 
targets to overcome the constellation of metabolic disturbances. 
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